Closed Calls for Proposals

Aim: Grant applications responding to this call must propose highly innovative approaches that have the promise of pioneering new ways of thinking about cancer biology and therapeutics.

Funding: $70,000 per year for 2 years.

https://www.icrfonline.org/grants/

https://www.icrfonline.org/wp-content/uploads/2021/10/Acceleration-Grant-Policies-10-2021R.pdf

(Research authority deadline: 5.8; MOST deadline: 12.8)

Collaborative projects with partners from the German Cancer Research Center (DKFZ), all topics related to cancer research, except for clinical trials.

Updated information on the DKFZ, can be found at: https://www.dkfz.de/en/forschung/index.html

For eligible partners from DKFZ: https://dktk.dkfz.de/en/research/dktk-researchers

Funding: € 43K / yr for 3 years (for the Israeli side). 6 joint projects will be funded.

Please contact research authority if planning to submit (overhead).

https://www.gov.il/he/departments/publications/Call_for_bids/most_rfp202100613

Supports established institutes or centers in mathematics, theoretical physics and theoretical computer science to help strengthen contacts within the international scientific community. Funding: $200K / year for up to 3 years. Nonprofit

https://www.simonsfoundation.org/grant/targeted-grants-to-institutes/

(ISF pre-registration by Aug. 5, ISF deadline Aug. 12)

Aim: to encourage research cooperation between Japanese and Israeli scientists. Eligible: investigators with active ISF grants with at least 2 years remaining. Funding: NIS 38K over 2 years (No Overhead).

http://isf.org.il/#/support-channels/42/10

The program supports consortia of minimum 4 partners eligible for funding (see in the call) from 4 different countries.

Topics List :

Research studies on therapies using small molecules, small non-coding chemically synthesized nucleic acid-based therapies, repurposed drugs or biologicals (e.g., antibodies or proteins such as enzymes, immune modulators or growth factors etc.). Proposals must cover at least one of the following areas: 1. development of novel therapies in a preclinical setting through cell, organoid and animal model studies, molecule screening or use of in silico or artificial intelligence models 2. development of predictive and pharmacodynamics biomarkers correlated to the efficiency of the therapy in a preclinical setting that could serve as surrogate endpoints  3. replication of pre-clinical studies in an independent lab to increase validity of exploratory findings 4. pre-clinical proof of concept studies for evidence of pharmacological activity in vitro and in vivo, pharmaco-kinetics and pharmaco-dynamics of the drug and first toxicology and safety data  5. studies to support readiness for initiating clinical trial authorization conforming to regulatory requirements Translatability into humans should be the key focus of the project, and applicants should demonstrate access to relevant scientific or regulatory expertise (e.g., through innovation task forces or competent national authorities).  Funding for the Israeli partner: €140,000 over 3 years. (€160K for coordinator)

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272).

https://erdera.org/wp-content/uploads/2024/10/Pre-announcement-JTC-2025_final-1.pdf

https://erdera.org/

https://erdera.org/funding/#joint-translational-call

The overall objectives of the JTC2025 will be to

• Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:

o    identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.

o    validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.

o    use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).

• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
• Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Funding for the Israeli partner: €140,000 over 3 years.

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272).

https://www.eppermed.eu/news-events/news/ep-permed-jtc2025-pre-announcement-pharmacogenomic-strategies-for-personalised-medicine-pgxpm2025/

Description: Instruct-ERIC provides funding to support access to structural biology research infrastructures. The program covers the costs of infrastructure use, travel, accommodation, and consumables.

Benefits: Comprehensive support for conducting research in structural biology, including access to advanced facilities and expert assistance.

Success Rate: Applications have a high success rate of 70-80%.

Target Audience: Researchers in the field of structural biology seeking to utilize advanced infrastructure for their projects.

Instruct-ERIC Access Funding

If planning to submit, please update the RA

Multinational, collaborative research projects that will address critical translational and clinical questions using interdisciplinary approaches to improve the knowledge about the neuroscience of pain, bearing the potential to improve the lives of the people affected.

Minimum 3 partners eligible for funding from 3 different countries. Up to 5 partners in total.

Funding for the Israeli partner: €140,000 over 3 years.

* A short abstract and budget should be sent to the ministry of Health (MOH) prior to pre-proposal submission. Call us for clarifications and MOH abstract forms (tel. 2152, 1272).

www.neuron-eranet.eu/joint-calls/bio-medical/2025-pain/

www.neuron-eranet.eu/wp-content/uploads/JTC2025_preliminary_announcement_Dec24.pdf

Address a critical bottleneck in the development of PM solutions: the validation phase. Seeks to give support to overcome validation challenges by providing a structured, accelerated pathway for PM innovators to validate their solutions.

For researchers and entrepreneurs with a product or service in personalized medicine that is not in the commercialization stage, but at least at TRL 3.

Allow access to validation centers: live laboratories, databases, innovation centers, hospitals, and more.

Funding: up to 80K EUR for 6 months (min 70% of budget to validation services)

https://www.eppermed.eu/wp-content/uploads/24-12-10_Fast-Track-Call_Final.pdf

https://www.eppermed.eu/funding-projects/calls/fast-track-call/

Information webinar: January 21, 12:00-13:00, for registration:

https://events.teams.microsoft.com/event/0c378a7e-e8c7-488a-ab81-7ea3deab5ba5@c5c9deae-d8b0-4fe6-8d11-6c43bcb151e4

Q&A meeting: March 4, 12:00: https://shorturl.at/XGuAP

The EP PerMed offers a Venture Creation program (not funded), a hands-on learning program for entrepreneurs in the field of personalized medicine. For more details:

https://www.eppermed.eu/wp-content/uploads/Venture-Creator-Call.pdf

Venture Creator – European Partnership for Personalised Medicine – EP PerMed

Through this call, Instruct allocates funds to support up to four small pilot research and development projects in any area of structural biology up to a maximum of €15,000 per project. Projects should propose research which is preliminary in nature with an expectation of collecting data that may be included in support of an application for more substantial funding through conventional routes. The proposal is required to contain aspects of technology and/or software development within integrated structural biology to be considered for the award. All proposals must include the use of technologies available at Instruct Centres or develop technologies that will benefit the aims of Instruct. This call is specifically aimed at early career researchers as defined in the EU ERC Starting Grant programme. The ERC eligibility criteria comprise researchers with two to seven years of experience since completion of their PhD as well as a scientific track record showing great promise and an excellent research proposal.

If planning to submit, please update the RA.

https://instruct-eric.org/submit-call/instruct-eric-pilot-rd-project-call-2025

Collaborative research projects with Niedersachsen (Lower Saxony, Germany) region (including Hannover, Göttingen, Braunschweig, Osnabrück, Oldenburg…).

Funding: up to €500K for up to 4 years (no overhead).

https://zukunft.niedersachsen.de/en/funding-offers/research-cooperation-lower-saxony-israel/

FAQ: https://zukunft.niedersachsen.de/wp-content/uploads/2024/11/FAQ_Research_Cooperation_Lower_Saxony_Israel.pdf

NDS Research institutions: https://www.lower-saxony.de/education_and_science/research/institutions/-99274.html

האגודה למלחמה בסרטן: קול קורא להגשת הצעות מחקר
מענקים לחקר מחלות סרטן:
• מחקר קליני ובסיסי
• עדיפות למחקר המשלב אספקטים קליניים ובסיסיים
• מחקר אפידמיולוגי ואפידמיולוגי- גנטי
• רפואה מותאמת אישית – Personalized medicine
מימון: 180,000 ₪ למשך שנתיים.
* מחקר התנהגותי הקשור לחולי סרטן במחלות שונות – 100 אלף ₪ לשנתיים.
* מחקר בתחום הסיעוד האונקולוגי – עד 100 אלף ₪ לשנתיים.
* מסלול אופציונלי לחוקרים צעירים – יוענקו מענקים של עד 75 אלף ₪ לשנתיים.
* שיתוף פעולה עם חוקר הולנדי – 180,000 ₪ לשנתיים.
* מתוך כלל המענקים תיבחרנה עד 5 הצעות מחקר שתימצאנה ראויות לקבלת מענק מצטיין בסך 360,000 ₪ לשנתיים.
שימו לב: אין כיסוי לתקורה.
האגודה מעודדת עבודות מחקר בנושאים הקליניים, ההתנהגותיים והאפידמיולוגים, ומעודדת מחקרים קליניים ובסיסיים המבוצעים ע”י רופאים המטפלים בחולים.
עדיפות להצעות בעלות פוטנציאל ליישום קליני, שתתבססנה על שיתוף פעולה בין רופאים לחוקרים במדעי היסוד. וכן להצעות מחקר שתוגשנה ע”י רופאים.
https://www.cancer.org.il/articles/11095/

Research authority deadline: 7.8 | MOST deadline: 14.8
Collaborative innovative and potentially applicable projects with partners from the German Cancer Research Center (DKFZ), all topics related to cancer research, except for clinical trials.
The potential for cancer therapy should be clearly pointed out.
Updated information on the DKFZ, can be found at: https://www.dkfz.de/en/transfer/cooperations/internationale-kooperationen/israel-cooperation
Funding: 43K€ (~172K NIS) per year for 3 years (for the Israeli side). 6 joint projects will be funded.
If interested, please contact the research authority to check your eligibility.
https://www.gov.il/he/pages/rfp18062025

Supports the organization of transnational networking events that promote knowledge sharing, research uptake and collaborations among clinicians, researchers, and patients/patient advocacy organizations (PAOs).
Funding: up to €30K per networking event
https://erdera.org/nss/

האגודה למלחמה בסרטן: קול קורא להגשת הצעות לפרויקטים ו/או מחקרים קליניים או אפידמיולוגים בתחום המניעה והגילוי המוקדם

יוענקו מספר מלגות לבקשות שיעסקו בביצוע והערכת פרויקטים יישומיים לקידום תוכניות למניעה וגילוי מוקדם, ולבדיקת היתכנות של טכנולוגיות חדישות ליישום קליני, תוך מתן עדיפות לפרויקטים שיופעלו בקהילה ו/או יציגו שיתוף פעולה בין מספר מרכזים.

מימון: ארבעה פרויקטים יזכו בסכום של עד 25,000 ₪, שני מחקרים/פרויקטים מצטיינים במיוחד יזכו במימון של עד 50,000 ₪. ללא תקורה.

https://www.cancer.org.il/articles/8011/

משרד הבריאות – חטיבת טכנולוגיות רפואיות מידע ומחקר: קול קורא למחקרים הבוחנים פתרונות חדשניים לקידום רגולציה של טכנולוגיות רפואיות

מטרת הקול קורא:

להיחשף להתפתחויות ומגמות מתקדמות, לבחון אמצעים חדשניים שיביאו לשינויים או גישות חדשות בתהליכי הרגולציה ובנוסף הידוק הקשר בין בעלי העניין השונים במערכת, קידום המערכת הרפואית והטיפול הרפואי לטובת בריאות הציבור.

נושאי מחקר מועדפים:

–  כלים חדשניים לחיזוק שיתוף הפעולה בתחום החדשנות בין חטיבת הטכנולוגיות והאקוסיסטם .

–  בינה מלאכותית ככלי תמיכה בקבלת החלטות: הערכה רגולטורית של טכנולוגיות רפואיות, ניסויים קליניים כולל הליכי IRB , טכנוויג’ילנס (מעקב אחרי האישור והרישום של מכשור רפואי ופארמה).

–  קריטריונים להערכת איכות נתונים ושילוב ראיות מהעולם האמיתי (RWE) בהחלטות קליניות (לדוגמא לצורך תיכנון ניסויים קליניים, הערכת טכנולוגיות וכדומה).

–  אסטרטגיה לאומית לנתוני בריאות וכלים ליישום (כגון איפון והנגשה של מאגרי מידע לחוקרים ולתעשייה).

מימון: 80 אלף ₪ לשנה (כולל 10% תקורה).

https://www.trdf.co.il/files/MOH_call.pdf

https://www.trdf.co.il/files/Application_form_MOH.docx

Submission to Biodiversa+:  7.11, 12:00 CET | Sumbission to MOE: 11.11, 12:00 

Please contact us if interested in submitting, the submission process is complex (ra-tec@trdf.technion.ac.il)

This call is focused on fostering innovative research to be integrated into nature restoration practices for interconnected and well-functioning ecosystems and habitats, with special consideration for long-term sustainability and future-proofing of restoration efforts, at scales from local to regional to cross-border and global, including their evaluation.

. Project proposals can address one or more of these main topics.

Topic 1: Setting restoration targets and measuring success

Topic 2: Transferability and scaling of nature restoration efforts

Topic 3: Resilience and sustainability of restoration efforts

To be eligible, research consortia will have to include:

• Teams from a minimum of three countries financially participating in the Call,
• With at least two of these from EU Member States or EU Associated Countries.

Open Call – Biodiversa +

מכרז פומבי (קול קורא) בנושא שיקום תפקודהּ, שְׁלֵמוּתָהּ וְקִישּׁוּרִיּוּתָהּ של המערכת האקולוגית – BiodivConnect המשרד להגנת הסביבה

חיל הרפואה במסגרת הכנס הלאומי לרפואה צבאית: פרס מצוינות במחקר

פרס מוענק על תרומה מדעית פורצת דרך ובעלת השפעה רחבת היקף על בריאותם ורווחתם של משרתי מערכת הביטחון בכל מעגלי החיים – מרפואת השגרה, דרך הטיפול בפצועי קרב ובבתי החולים, ועד לתחומי בריאות הנפש והשיקום.

https://www.trdf.co.il/files/Medical corps award.pdf

מצטיינים במחקר

Research to characterise misophonia, including exploring its underlying mechanisms, expression, natural history, or development through interdisciplinary characterisation.

• Development of diagnostic tools to facilitate rapid, physiologically-relevant assessment.
• Clinical and/or model studies of specific interventions, including studies investigating comparative effectiveness, novel treatments, and controlled trials of promising treatments.

Funding: up to $200,000/year up to two years. Non-profit.

https://misophoniaresearchfund.org/scientific-funding/

To grow the global base of movement disorder specialists — neurologists with additional training in Parkinson’s disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.

Funding: $180,000 for 2 years.

https://www.michaeljfox.org/grant/edmond-j-safra-fellowship-movement-disorders

Academy of Kidney Cancer Investigators – Early-Career Investigator Award: $725,000 for 4 years.

Clinical Research Nurse Development Award: up to $300,000 for 2 years.

Clinical Trial Award: $2,000,000 for 4 years.

https://ebrap.org/eBRAP/public/Program.htm

Research projects that will have an impact on leukemia. MDS (Myelodysplastic syndrome) proposals will also be accepted.
New investigators are considered to be within 7 years of their first independent faculty-level position when the grant would be awarded. Applicants with any active single grant (or multiple grants added together) that total $175K or greater in total direct costs per year are not eligible.
Funding: $150K over two years. No overhead.
https://leukemiarf.org/research/grant-programs/guidelines-application

To fund research addressing unmet medical needs in the diagnosis and treatment of potentially lethal prostate cancer. Applicants may be working in basic, translational, computational or clinical research and need not be trained specifically in prostate cancer research to be highly competitive. However, successful applicants should be working in an academic research environment capable of supporting transformational prostate cancer research. Access to and real-time interaction with a clinical environment and translational prostate cancer physician-scientists is highly desired.

Funding: $75 per year for 3 years

https://www.trdf.co.il/files/RFA_2025-Young-Investigator-Award.pdf

To solicit collaborative research ideas focused on the intersection of genomic testing and routine practice in the care of patients with advanced prostate cancer.

No financial support will be provided to investigators for awarded projects. Project awardees will be paired with a Foundation Medicine data scientist and receive indirect access to the CGDB database to collaboratively evaluate research hypotheses with the goal of producing high-impact conference abstracts and peer-reviewed publications that provide tangible insights to improve the care of patients with prostate cancer.

https://www.foundationmedicine.com/proposals-advance-prostate-cancer-research-precision-medicine

To advance the understanding of the origins and risk stratification of recalcitrant cancers and accelerate the development of technological and methodological innovation in early cancer detection and interception. Eligible Cancer Types:

– Pancreatic cancer

– Hepatobiliary cancers (hepatocellular carcinoma, gallbladder and bile duct cancers, cholangiocarcinoma)

– Ovarian cancer

– Glioblastoma

– Upper GI cancers (esophageal, gastric cancer)

– Cancers resulting from hereditary cancer predisposition syndromes

Funding: up to $2M for 2 years, 2-4 investigators per project

https://themarkfoundation.org/early-detection-award/

Support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer.

Funding: $3M over 3 years (Non profit)

https://themarkfoundation.org/endeavor/

Translational and clinical research to advance allograft tissue transplantation science and patient care. Projects must utilize allografts or allograft-derived materials and must have a strong clinical translation component.

Junior Investigator – qualified junior investigators who have not previously received a major grant award, funding: $75K for 1 year

Established Investigator – qualified experienced investigators who have previously received a major grant award, funding: $225K for 3 years

https://www.mtfbiologics.org/who-we-serve/donors-community/researchers

(more deadlines on June 15, Sep 15, Nov 15)

Supporting breakthroughs in life science research areas, including but not limited to those indicated below. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

Funds early-stage science with unique hypotheses fostering the next generation of congenital heart defect and related pediatric heart disease research, thus, creating a strong foundation of preliminary evidence to make scientific advancements. Encourages research to determine hidden causes and discover cures to prolong, improve and save the lives of all children afflicted with CHDs and related pediatric heart diseases. Proposals can be basic science, translational, or clinical in nature. Proposals focused on the impact of COVID-19 are also invited.

Funding: up to $100,000 for one year.

https://savingtinyhearts.org/research/grant-application

The purpose of the Fund is to provide grants for clinical, hypothesis-driven research that offers substantial promise for meaningful advances in the prevention, diagnosis and treatment of children’s diseases, particularly research that offers broad-based applications.

Funding: up to $25K for 2 years.

Eligibility: 1. Physicians who are in a residency/fellowship training program, or who completed that program no more than one year before the Concept Paper deadline.  2. Post-doctoral researchers who received the doctoral level degree no more than 3 years before the Concept Paper deadline.

www.thrasherresearch.org

To support non-interventional Investigator Sponsored Research projects that will advance the understanding of IB6 patterns of expression and clinical outcomes in NSCLC or explore sigvotatug vedotin’s preclinical activity.

Funding: $200K for 18 months

https://cdn.pfizer.com/pfizercom/2025-01/GMG-2025-ONC-Global-IB6TranslationalPreclinical-RES-final.pdf?VersionId=zvcR0YkUuAxQHrRuunIGK4tRvFk8n2W9

For outstanding research contributions to the field at the fundamental and/or translational level.

Funding: $100K prize money and the Emory Max Cooper Prize in Immunology Medal.

https://med.emory.edu/research/research-innovation/max-cooper-prize.html

With the Research Grants in open competition program, the LEO Foundation aims to support the best dermatology research projects worldwide, within basic, translational, technical, epidemiological, or clinical research. We welcome applications for research projects that improve the understanding of skin biology, as well as the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms. We also welcome applications that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life, and the societal costs involved.

Funding:  up to 4 Million DKK (~$560K) for 1-3 years.

https://leo-foundation.org/en/grants-and-awards

https://leo-foundation.org/en/grants-and-awards/research-grants

The LEO Foundation Awards recognize outstanding young researchers (30-40 years of age) and scientists from around the world whose work represents an extraordinary contribution to skin research and has the potential to pave the way for new and improved treatments for skin diseases. A LEO Foundation Award is worth USD 100,000.

https://leo-foundation.org/en/grants-and-awards

https://leo-foundation.org/en/grants-and-awards/research-grants

https://leo-foundation.org/en/wp-content/uploads/sites/2/2024/11/LEO-Foundation-Award-Application-guide-2025-1.pdf

Provide support for multi-investigator-initiated clinical research projects to test new hypotheses and/or new methods (pilot and feasibility) or to advance established results with the potential to address diagnosis, treatment, management of disease or symptoms, or the pathophysiology of cystic fibrosis using clinical (observational/interventional), translational, or epidemiologic study approaches.

Funding: up to $200K per year for up to 3 years

https://www.cff.org/researchers/multiple-principal-investigator-clinical-award#policies-and-guidelines

Seeks to stimulate creative approaches to translate basic research into new treatment options for ocular/uveal melanoma.

Funding: $50K for 1 year (No overhead)

https://www.aacr.org/grants/aacr-ocular-melanoma-foundation-miriam-counts-innovation-and-discovery-grants/

Can we program plants to remove more CO2, improve food security, and deliver medicines to those in need?

Please note that primary focus is on funding those who are based in the UK. Partnerships with a UK based organization is allowed / projects that will primarily take place outside of the UK can be funded, if are unique/compelling.

Funding: from £10k up to £500k per up to 3 years

https://aria.org.uk/opportunity-spaces/programmable-plants/programmable-plants

Understanding the expression of the PCDH19 gene and the function of the PCDH19 protein, finding therapeutic treatments, and a cure for PCDH19 Epilepsy.

Funding: up to $75K for one year.

www.pcdh19info.org/research-grant-program

(Additional deadlines are on 1.8, 1.11)

Funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.

Funding: typically awards grants in the $50K-$300K range for 1-3 years, but there is no minimum or maximum funding level restriction (No Overhead)

https://sens.org/our-research/submit-a-grant-proposal/

Pioneer Award

Encourage and support innovative basic and/or clinical scientific research in the area of Inflammatory Bowel Diseases (IBD) across Europe.

Funding: 300K EUR for 2 years

Global Grant

Extend the outreach and global perspective of IBD research and may focus on aspects of IBD pathogenesis (e.g. environmental impact, genetics), epidemiology and/or clinical care, among others. Applications must be multicenter and address knowledge gaps and/or unmet needs relevant to low and lower-middle income countries and feature strong contributions from these countries. At least one Principal Investigator who is from a low- or lower-middle income country.

Funding: 300K EUR for 2 years

https://www.ecco-ibd.eu/science/fellowships-and-grants.html

With efforts to improve technology and affordability, mAb costs have decreased significantly in the last 30 years and have stagnated at around $50-100 per gram. In order to improve mAb affordability in low- and middle-income countries, we will need to reach a final drug substance cost-of-goods of $10 per gram.
Proposals are solicited to develop proof-of-concept for manufacturing platforms that produce monoclonal antibodies at a final drug substance cost-of-goods of $10/gram (Option A (application by 31.1.25)). The goal is to catalyze and accelerate multiple, diverse, innovative bioprocessing approaches that hold the promise of low cost-of-goods mAbs.
Additionally, Gates Foundation is interested in hearing from organizations that have already completed proof-of-concept work that could result in cost-of-goods of $10/gram and may be interested in additional support (Option B (application by 31.5.25)).
Objectives of the challenge (both Option A and Option B):  Advance innovative and bold ideas that enhance production efficiency and improve overall process economics for mAb production, resulting in a final drug substance cost-of-goods of $10/gram. This includes, but is not limited to:
* Alternative hosts to mammalian cell culture
* Alternative to standard downstream purification methods
* Reduction in material costs
* Push the boundaries of current technology by harnessing disruptive innovations, possibly from parallel industries, and identify process improvements to reduce manufacturing costs
* Rethink existing methods of working such as release testing process and costs, high-quality and affordable raw materials and critical reagents
Funding: Option A: up to $750K for up to 18 months.  Option B: Potential funding and grant terms will be evaluated on a per-project basis.
https://gcgh.grandchallenges.org/challenge/innovations-exceptionally-low-cost-monoclonal-antibody-mab-manufacturing

Catalyst Award

Prioritizes projects that advance research to clinical trial readiness. This includes the development of biomarkers and optimization of promising new entities with established proof-of-concept to improve pharmacokinetics/pharmacodynamics, safety profiles, and/or formulations to advance these new entities further in development.

Funding: max of $120K for 1 year (No Overhead)

https://www.trdf.co.il/files/CATALYST AWARD.pdf

Rare Epilepsy Partnership Award

An overarching goal of this funding mechanism is to develop resources and data that will be made available to the research community to accelerate research on rare epilepsies.

Funding: max of $100K for 1 year (No Overhead)

https://www.trdf.co.il/files/REPA-Guidelines_Final.pdf

(more deadlines on Sep 15, Nov 15)

Supporting breakthroughs in life science research areas, including but not limited to those indicated below. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

For 2025, the HMRC has identified relevant areas of research in the field of anti-doping; in particular, those related to the 2024 List of Prohibited Substances and Methods.

It should be noted that higher priority will be granted to proposals addressing:

 Detection/improvement of detection/quantification of peptide and protein hormones and growth factors, preferably by, but not limited to, chromatography-mass spectrometric methods;

 Improved window (retrospectivity) of detection of prohibited substances/methods (e.g., detection of new longterm metabolites including administration studies, improved methodologies of detection, analyte multiplexing);

 Pharmacokinetic studies to establish thresholds or minimum reporting levels of prohibited substances or their metabolites (e.g., beta-2 agonists, stimulants) to distinguish permitted (e.g., out-of-competition or route) from prohibited use, natural sources vs. intended use or presence in food residues;

 Detection of autologous blood transfusion, including validation of candidate biomarkers or molecular/cellular/subcellular signatures;

 The Athlete Biological Passport (e.g., new biomarkers of doping or confounding factors relevant to the hematological, steroidal or endocrine [markers of growth hormone] modules); and

 Selected Certified Reference Material synthesis (please consult WADA for materials needed).

Funding: not mentioned. No overhead.

https://www.wada-ama.org/en/news/wada-launches-call-proposals-2025-scientific-research-grants

The purpose of the Fund is to provide grants for clinical, hypothesis-driven research that offers substantial promise for meaningful advances in the prevention, diagnosis and treatment of children’s diseases, particularly research that offers broad-based applications.

Funding: up to $550K for 3 years.

www.thrasherresearch.org

(Additional deadline on 1.11)

Funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.

Funding: typically awards grants in the $50K-$300K range for 1-3 years, but there is no minimum or maximum funding level restriction (No Overhead)

https://sens.org/our-research/submit-a-grant-proposal/

With the Research Grants in open competition program, the LEO Foundation aims to support the best dermatology research projects worldwide, within basic, translational, technical, epidemiological, or clinical research. We welcome applications for research projects that improve the understanding of skin biology, as well as the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms. We also welcome applications that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life, and the societal costs involved.

Funding:  up to 4 Million DKK (~$560K) for 1-3 years.

https://leo-foundation.org/en/grants-and-awards

https://leo-foundation.org/en/grants-and-awards/research-grants

(another deadline on Nov 15)

Supporting breakthroughs in life science research areas, including but not limited to those indicated below. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

Funds external research with potential to accelerate the development of rejuvenation biotechnology. Applicants for financial support will be expected to clearly indicate the specific SENS target(s) addressed and explain how their proposed research would further progress toward therapies that remove, repair, replace, or render harmless that target.

Funding: typically awards grants in the $50K-$300K range for 1-3 years, but there is no minimum or maximum funding level restriction (No Overhead)

https://sens.org/our-research/submit-a-grant-proposal/

Supporting breakthroughs in life science research areas. This program is designed to empower researchers by providing grant funding earmarked explicitly for purchasing GenScript reagents and services.

Funding: $100K for up to 12 months

https://www.genscript.com/grantprogram.html

Collaborative Research Development Grant: ovarian cancer research that may involve several investigators. Interdisciplinary collaborations are encouraged.

Funding: $300,000 annually for 3 years

Collaborative Research Development Grant – Microsoft AI for Health

OCRA is partnering with Microsoft AI for Health, which offers access to advanced Microsoft Azure cloud computing and collaboration with data science experts for researchers working on challenges in the area of health, including ovarian cancer. Investigators funded through this grant opportunity have access to support from Microsoft in the form of Azure computing credits, and in-kind data science support.

Funding: $300,000 annually for 3 years

Early Career Award: junior faculty with a strong commitment to an investigative career in the field of ovarian cancer research.

Funding: $150,000 per year for 3 years

Mentored Investigator Award: provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research, or relevant area.

Funding: $100,000 to be used over 1 or 2 years

https://ocrahope.org/research/for-grantees/current-programs/

https://ocrahope.org/research/information-for-researchers/grant-programs/

https://ocrahope.org/research/information-for-researchers/apply-for-a-grant/

Projects that bring together investigators from diverse scientific disciplines are highly encouraged.
Accelerator Awards
To fund groundbreaking projects with the potential for transformative advancements in neuroendocrine cancer research and treatment. We seek proposals that push the boundaries of innovation, fostering synergistic collaboration across diverse scientific disciplines.
Funding: $800 for 4 years($200K/year)
https://netrf.org/for-researchers/about/funding-for-researchers/accelerator/
Investigator Awards
Seeks investigators and teams of investigators from around the world to study neuroendocrine cancers in new ways. Supports transformative basic, translational, and clinical research studies that address critical questions to advance our understanding of tumor biology, address roadblocks to therapeutic development, and/or exploit innovative technologies or strategies.
Funding: $270 for 2 years
https://netrf.org/for-researchers/about/funding-for-researchers/investigator/
Pilot Award
Designed for pilot/feasibility studies.
Funding: $90 for 1 year (No overhead)
https://netrf.org/for-researchers/about/funding-for-researchers/pilot/

Accepts applications in all areas of research relevant to PWS, but we are particularly interested in Supporting projects that will lead to new interventions to alleviate the symptoms associated with PWS.
Funding: up to $150K for 18 months
https://www.fpwr.org/grant-program

Supports fundamental or translational research into the prevention, diagnosis or treatment of cancer.

Welcomes research projects with a strong scientific hypothesis that draws on epidemiological, behavioural and clinical data to provide a starting point for a new avenue of research (any type of cancer)

Only the first 500 applications submitted will be accepted by the foundation.

Funding: up to £275K over 1-3 years. (No overhead. Non-profit)

https://www.worldwidecancerresearch.org/for-researchers/

To pump-prime early stage research to generate preliminary data that can be put towards future funding proposals. For innovative and novel ideas related to prevention, diagnosis and/or treatment of human diseases. Can be used in UK Universities and Research Institutes or research in other countries (e.g. fieldwork for studies of infectious disease) but the grants have to be administered and disbursed by a UK University or Institution.
Funding: £20K over 12 months for preclinical studies and over 18 months for clinical studies.
https://rosetrees.org.uk/seedcorn-awards/

The Award will recognize new and significant contributions to the development of sustainable wet and dry labs with a focus on their environmental impact.

Applications are evaluated using the following criteria:

Direct and indirect longitudinal impact of the project on the environment, institutional culture and community, including opportunities for expansion and scale-up

Diversity of stakeholder groups involved in or affected by the project

Creative and visionary thinking that offers new perspectives with a particular sensitivity to the systemic aspects of the topic.

The award winner will have the opportunity to present their initiative or project at scientific events and will be supported with a grant of 10,000 euros.

www.embo.org/the-embo-communities/embo-lab-sustainability-award

Applicants must have been an independent group leader for at least one year and for less than 4 years at the pre-application deadline (having started no earlier than 1.4.21 and no later than 1.4.24), for the application round 2025.  EMBO Young Investigators receive a financial award of 15K EU in their 2nd year. They can also apply for additional small grants of up to 10K EU per year. Networking is a key aspect of the programme, and Young Investigators benefit from extensive practical support.

www.embo.org/funding/fellowships-grants-and-career-support/young-investigator-programme

https://oc.embl.de/index.php/s/bVA6ZQF4BDWwzfm

Swiss Bridge Award has been granted to support high-quality cancer research projects in Europe. This year, young investigators (Age < 45) with projects focusing on novel targets in precision oncology are eligible for application.
Funding: ~$277K (250K CHF)
www.swissbridge.ch/call-for-application

Invites collaborative teams to apply for the ASAP Collaborative Research Network (CRN). This international, multidisciplinary network focuses on advancing Parkinson’s disease (PD) research.

Current Call: Scientific Track

Seeking proposals on PD heterogeneity within one of six focus areas:

• Aging & PD
• Co-pathologies
• Environmental risk factors
• Circuit biology (non-motor symptoms)
• Clearance mechanisms
• Seeding in α-synuclein assays

Eligibility & Funding

• Teams:3–5 PIs (incl. one early-career), from 2–5 institutions
• Funding:$3M/year for 3 years

Funding details
Full RFA

Kabiller Prize
Recognizes individuals who have made a significant, career-long impact in the field of nanotechnology applied to medicine and biology. It is the world’s largest monetary award for outstanding achievement in the field.
Funding: $250K
Kabiller Young Investigator Award
Recognizes individuals who have made groundbreaking discoveries within the last few years in the same area that have the potential to make a lasting impact.
Funding: $10K
The Kabiller Rising Star Award
Presented to talented, early-career faculty scientists in recognition of the exceptional potential of their contributions to nanoscience.
Funding: $3K
https://www.iinano.org/education/kabillerprize/

Supports early career researches with a vested interest in furthering cancer immunotherapy research and translational immunotherapeutic approaches for the treatment of DLBCL, FL, and CLL.

Please note: for applicants prior to obtaining a tenure track faculty position, no more than four years from completing  postdoctoral training. Mentoring required.

Funding: $100K for 1 year

https://sitcancer.org/professional-development/fellowships/fellowships-2025/

Please contact the Research Authority in advance if you consider applying (ra-tec@trdf.technion.ac.il).

The program focuses on the discovery of direct-acting small molecule antibiotics with broad-spectrum activity against Enterobacteriaceae, using Klebsiella spp. as the pathogen to initiate a discovery program.  Proposals must address at least one of the following themes:

1. Development of genome-scale tools or other innovative technologies to identify new chemical starting points linked to targets as well as assessment of potential drug target vulnerability, singly or in combination.
2. Development of innovative technologies to select targets and chemical leads with a very high bar to resistance.
3. Gaining a better understanding of the chemistry underlying penetration of compounds to different compartments of the bacterial cell to build a platform to rapidly test whether compounds reach and accumulate at their target.
4. Development of novel and coordinated approaches to identifying new chemical leads for clinically or in vivo validated drug targets, for which there is currently no agent in Phase 3.

Funding: Up to $5 million over 3 years.  Exploratory projects with shorter durations or lower budgets that focus on high-risk, innovative areas are strongly encouraged and will be given priority.

The program particularly encourages applications from ‘low- and middle-income countries’ (LMICs) and projects led by women and other groups that are historically under-represented in the drug discovery field. All applications received will then be reviewed on their merits.

** If interested, register to a dedicated webinar on February 27, from 6:00 to 7:00 AM Pacific Time., for a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance. The webinar will be recorded and available on this challenge page after the session.

https://gcgh.grandchallenges.org/challenge/innovations-gram-negative-antibiotic-discovery

Proposals for innovative solutions for the early detection, prevention, and treatment of preeclampsia, particularly in low- and middle-income countries (LMIC) where maternal mortality rates are high. To support this focus, we are looking for collaborations, including those with research institutions, health care providers, and global health organizations, that enable cross-sector insights and ensure that solutions are adaptable and practical.  The objectives of the challenge are:

* Early prediction and detection of preeclampsia – biomarkers (including other than sFlt1 and PlGF), diagnostic tests, and point-of-care technologies to predict early in pregnancy the risk of preeclampsia and to diagnose it before symptoms become severe.

* Understanding the pathophysiology of preeclampsia and its heterogeneity. We seek to understand the biological mechanisms driving the disease and its subtypes so that new interventions can be effectively tailored to the underlying etiology.

* Preventive and therapeutic interventions. We seek new approaches to known targets or new targets to reduce the incidence and severity of preeclampsia, mitigate disease progression, and prevent the cardiovascular and metabolic complications that often follow it.

Funding:  up to $500K over 2 years.   Particularly encouraged are applications involving projects led by women or from women-led organizations and applications from institutions based in LMIC.

** If interested, register to a dedicated webinar on February 27, from 7:30 to 8:30 AM Pacific Time for a comprehensive overview of the RFP details and an opportunity to have your questions answered. To participate in the webinar, please register and submit your questions in advance. The webinar will be recorded and available on this challenge page after the session.

https://gcgh.grandchallenges.org/challenge/reducing-burden-preeclampsia

EB research priorities:
– Drug repurposing and drug discovery
– Patient-centered research themes
– The causes and progression of EB
– Raising a new generation of EB researchers
Small grant: to support small pilot studies such as generation of preliminary data or feasibility studies which would not normally attract funding. The aim is to make larger follow up funding grants more competitive.
Funding: up to £15K
Large grant: applicants must demonstrate the potential benefit to EB patients in the research proposal. Funding will be judged on relevance to EB, scientific merit and novelty.
Funding: up to £200,000 for 2-3 years
https://www.debra.org.uk/eb-research/apply-for-funding/

Research Seed Funding Grant
To provide funds to develop exciting investigator-initiated concepts for research in medical physics.
Global Health Research Seed Funding Grant
– Research in emerging medical physics fields such as radiopharmaceutical therapies and expanding beyond the usual radiology and radiation oncology.
– Computational physics integrating AI/ML/DT technologies.
The applicant must be a member of AAPM with 10 years or less since receipt of a terminal research degree, excludes those who have reached Associate Professor. No previous grants >$50,000 as principal investigator
Funding: $25K (No overhead)
https://aapm.secure-platform.com/gaf/page/seed
https://aapm.secure-platform.com/gaf/page/GlobalSeed

To support high quality research on non-pharmacological treatment of symptoms experienced by patients with Parkinson’s disease and other movement disorders performed in a research center in or related to Switzerland.
The funding period is two years, with a possible extension up to a maximum of 4 years. It includes any support of the research project, with the exception of the applicant’s own salary.
https://www.jggf.ch/en/neurology-research

Supports groundbreaking scientific research that may lead the way to the cure or the improved therapeutic management of lymphoma. The aim of this call is to fund groundbreaking translational research on malignant lymphoma, malignant lymphoid neoplasia and related malignant blood diseases (particularly lymphoid disorders) that enhance our understanding and furnish insights or develop tools that will advance the treatment. Applications from individual researchers or research groups are welcome.

Funding: 1 M€ for 4 years (No overhead)

https://www.lymph-co.com/en/research-and-grants/lymphco-research-grant/

Researchers, in the US and abroad, who are working on novel approaches that may contribute substantively to scientific understanding of tinnitus, breakthroughs in treatments, and possible cures are encouraged to apply.

Funding for 1-2 years Research Grants: Established Investigators – $60,000;  Early Investigators – $25,000.

www.ata.org/apply-for-ata-grants/

These challenges represent the most urgent, complex problems in cancer research – problems that can only be solved through collaboration across borders and disciplines:

• AI-human collaborations in cancer
• Cancer avoidance
• The dark proteome
• Mechanisms driving mutational signatures
• The nervous system and cancer
• Rewiring cancer cells
• TME dynamics

Shortlisted teams are notified and given seed funding to support submission of a full application.
Funding: awards of up to £20m ($25m).

New challenges | Cancer Grand Challenges

Applications | Cancer Grand Challenges

A new flagship program to actively promote translational and clinical research.
Funding: 200K Swiss francs (~$232K)
https://osteology.org/en/research/funding-opportunities/applied-research-grants/

To encourage the development of novel approaches to address bladder cancer. Applications are invited from researchers currently in the field as well as investigators with experience in other areas of cancer or biomedical research who have promising ideas and approaches that can be applied to bladder cancer research.
Funding: $50K for 1 year (No overhead)
https://www.aacr.org/grants/aacr-grant-for-innovative-bladder-cancer-research/

Fund creative, innovative research into non-drug approaches that will play a vital part in helping people living with Parkinson’s manage their daily challenges and take control of life with Parkinson’s. These may include:
– Speech and language, physiotherapy and occupational therapies
– Approaches to managing mental health
– Lifestyle changes including exercise, dance and nutrition
– Aids and devices
– Complementary therapies
Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
Funding: up to £200K for up to 24 months
https://www.parkinsons.org.uk/research/grants-non-drug-approaches

To help pioneer and accelerate novel drug development for the treatment of Parkinson’s, providing researchers the opportunity to generate the essential data and help bridge the gaps needed to get their projects/compounds ready to enter full scale drug discovery with an industry partner or the Parkinson’s Virtual Biotech.
Co-applicants and collaborators may be based at institutions outside the UK or biotech companies.
Funding: up to £150K for 12 to 18 months, for projects involving in vivo work, an award amount of up to £200K will be considered.
https://www.parkinsons.org.uk/research/drug-accelerator-awards
Drug accelerator award workshop for applicants will be held on Jul 3, 4PM, for registration:
https://parkinsons-org-uk.zoom.us/meeting/register/

To provide catalytic funding for exploratory research projects within the thematic research areas pathogenic fungi, novel antimicrobial resistance (AMR) tools, and harnessing innate immunity.
Main applicant must be anchored in Denmark. International collaboration is encouraged.
Funding: 6.5M DDK (~954K USD) for up to 3 years
https://novonordiskfonden.dk/en/grant/infectious-diseases-catalyst-grants-2025/

Honoring those who’ve dedicated their careers to furthering the field of Neuroscience.
Outstanding Career and Research Achievements Awards, Early Career Awards, Honoring Support For Women, Science Education and Outreach Awards.
For the full list of Award and Prizes: https://www.sfn.org/initiatives/awards#lifetime

(another deadline on 3.10)
The Program supports investigator-initiated studies (IIS) and education projects on molecular profiling in oncology, with the goal to increase high quality molecular profiling and help democratize the future of precision medicine.
Funding: Up to $200,000 over one year.
www.thermofisher.com/il/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/clinical-research-grant-program.html
https://assets.thermofisher.com/TFS-Assets/CSD/Reference-Materials/Oncomine-Grant-Rules-2025.pdf

The Program supports investigator-initiated studies (IIS) and education projects on molecular profiling in oncology, with the goal to increase high quality molecular profiling and help democratize the future of precision medicine.
Funding: Up to $200,000 over one year.
www.thermofisher.com/il/en/home/clinical/preclinical-companion-diagnostic-development/oncomine-oncology/clinical-research-grant-program.html
https://assets.thermofisher.com/TFS-Assets/CSD/Reference-Materials/Oncomine-Grant-Rules-2025.pdf

Transforming Diagnosis Award:

Supports research seeking to transform diagnosis and prognosis to better determine the trajectory, long-term outcomes, and impact of AD/ADRD following military service and/or TBI.

Funding: up to $1.7M for 4 years

Transforming Research Award: Supports transformative research studies that reduce risk of or prevent the development of AD/ADRD with near-term, high-impact outcomes and demonstrate significant positive impact toward improving patient care and/or quality of life. Risk reduction considering TBI is of particular interest

Funding: up to $1M for 3 years

Transforming Care Award: Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both that clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not include medical care (such as medical interventions administered by a physician)

Funding: up to $31.8M for 4 year

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663104

Pilot Clinical Trial Award:

Applications must address one focus area: • Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. • Clinical Care: Improving aspects of clinical care and symptom management for ALS.

Funding: up to $2M for 3 years

Clinical Outcomes and Biomarkers Award: Supports the development and/or validation of clinical outcomes and/or biomarkers to enrich clinical trials in ALS.

Funding: up to $750K for 3 years

Therapeutic Development Award: Supports research ranging from preclinical validation of therapeutic leads through Food and Drug Administration Investigational New Drug (IND)- enabling studies

Funding: up to $1.5M for 3 year

Therapeutic Idea Award:

Supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

Funding: to $600K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663102

This RFP supports innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug development programs for frontotemporal dementia (FTD).

Funding: Up to $350,000 over one year.

LEARN MORE

https://www.alzdiscovery.org/research-and-grants/funding-opportunities

(another deadline on 2.10)

For UK institutions to invite an eminent senior professor from overseas, to bring genuinely novel expertise and enhance the skills and knowledge of academic staff and students in an underrepresented area in the UK. Priority will be given to new or recent collaborations and visits with a variety of activities beyond research. Applications will be considered in all subject areas except:
• studies of disease, illness and disabilities in humans and animals
• research that is intended to inform clinical practice or the development of medical applications
Funding: Applications are invited for £10K – £150K. Duration: 3-12 months. Grants between 3 and 6 months must be completed in one visit. Grants between 6 and 12 months can be spread over two or more visits.
https://www.leverhulme.ac.uk/schemes-at-a-glance

For UK institutions to invite an eminent senior professor from overseas, to bring genuinely novel expertise and enhance the skills and knowledge of academic staff and students in an underrepresented area in the UK. Priority will be given to new or recent collaborations and visits with a variety of activities beyond research. Applications will be considered in all subject areas except:
• studies of disease, illness and disabilities in humans and animals
• research that is intended to inform clinical practice or the development of medical applications
Funding: Applications are invited for £10K – £150K. Duration: 3-12 months. Grants between 3 and 6 months must be completed in one visit. Grants between 6 and 12 months can be spread over two or more visits.
https://www.leverhulme.ac.uk/schemes-at-a-glance

To early-career scientists advancing human immunology, vaccine discovery, and immunotherapy for major global diseases.
Researchers across scientific disciplines, including clinical research, biochemistry, molecular biology, protein engineering, computer science, artificial intelligence/machine learning, biophysics, and nanotechnology are encouraged to apply.
Funding: $150K for 1 year (No overhead)
https://www.michelsonmedicalresearch.org/michelson-prizes-next-generation

Support large-scale research projects concerning metastatic, lethal prostate cancer. PCF seeks high-risk, currently unfunded projects.
Research proposals in the following topic areas are solicited:
• Theranostics.
• Drugging currently undruggable oncology targets: preventing progression to lethal disease.
• Improved biotechnologies for precision medicine.
• First-in-field immunotherapies for prostate cancer.
• Artificial intelligence/machine learning to better inform patient outcomes.
• Host microbiome and tumor metabolism
Teams of at least 5 investigators from minimum 4 non-profit academic research institutions, Including 2 young investigators as integral
contributors. Cross-disciplinary teams that are diverse and inclusive will be favored.
Funding: $5 – $10M per award over 3–5 years
https://www.pcf.org/science-impact/for-researchers/open-rfas/
https://www.trdf.co.il/files/2025-TACTICAL-Award-RFA_4-8-25.pdf
https://www.trdf.co.il/files/LOI_Form_2025-TACTICAL_Awards.pdf

To promote and support early-career investigators* who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field.
The Inovitro® system (which will provided by Novocure, if needed), must be included in the experimental design.
* Received first faculty position with the title of assistant professor or the equivalent within the past 6 years (before December 1, 2025).
Funding: $300K for 3 years
https://www.aacr.org/grants/aacr-novocure-career-development-award-for-cancer-research-aacr-grants/

Funding for single or multiple investigators to address critical gaps and challenges and potential breakthroughs in Type 1 diabetes research.
Projects that hold a prospect for transformative breakthroughs that prevent, treat or cure type 1 diabetes will be given
top priority.
Funding: will be reviewed on a per-application basis.
https://www.breakthrought1d.org/explore-research/funding-opportunities/
https://www.breakthrought1d.org/explore-research/research-strategy/

Seeks to identify collaborators who have analytically validated biomarker assays to deploy in existing PPMI bio samples to enhance the biological definition of Parkinson’s disease (PD) and related disorders, both before and after symptom onset.
Funding: Up to $750K for 6 to 24 months
https://www.michaeljfox.org/grant/ppmi-biofluid-biomarkers-program

Wong Family Foundation Research Award
Research Award may include (but are not limited to):
Basic research in mechanisms relating to intractability, e.g., multi-drug resistant epilepsy
Model development (especially for infantile spasms or intractable epilepsy)
New technologies related to epilepsy (imaging, electrophysiology, etc.)
Research grants
Research grant proposals should address one of the following four high-priority areas:
Understanding phenotypic heterogeneity in TSC, i.e., research on genetic, biologic, or environmental factors that might explain why TSC is so different from person to person
Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
Improving TSC disease models, whether cell-based, tissue-based, or animal models
Developing clinical biomarkers or patient-reported outcome measures for TSC, particularly those that assess disease burden or stratify an individual’s risk of progression or developing specific manifestations of TSC
For early-career researchers. Fully supports collaborative projects between co-investigators.
Funding: $75K per year for 2 years
https://www.tscalliance.org/researchers/grants-funding/
The TSC Biosample Repository houses human biological materials such as blood, DNA, and tissues linked to detailed clinical data.
To request samples: https://www.tscalliance.org/research-strategy/biosample-repository/

IMRF provides research funding in the fight against connective tissue diseases, including, but not limited to emphysema and genetic diseases, especially those related to elastin and elastase concentrating in the causes as opposed to the cure or treatment of the disease. Research may also include the fields of immunology and bio-chemistry.
Funding: Up to $100K over 1-3 years (No Overhead).
https://www.mandlresearch.org/apply-1

Funds an established, leading PIs pursue a potentially ground-breaking, high-risk project in basic research in ALS.
Funding: 200K CHF (~880,000 NIS) for 2 years (one or two grants will be funded).
https://www.radala-foundation.com/index.html

Research Grant
Research grants are intended to encourage the development of new information that contributes to the understanding of the basic etiology and
pathogenesis of cystic fibrosis.
Funding: $150 per year for up to 3 years
https://www.cff.org/researchers/research-grants
Path to a Cure (PTAC) Research Grant
To facilitate or enable the development of new information that may contribute to the development of new therapies focused upon
repair or replacement of CFTR variants not served by existing small molecule modulators.
* Applicants seeking to submit proposals focused on topics such as mucociliary clearance and airway hydration, infection and inflammation,
or non-lung manifestations of disease should apply through the Research Grant mechanism.
Funding: $150 per year for up to 3 years
https://www.cff.org/researchers/path-cure-academic-programs

Pilot and Feasibility Awards
For developing and testing new hypotheses and/or methods, and supporting promising new investigators as they establish themselves in research
areas relevant to cystic fibrosis.
Funding: $50 per year for up to 2 years
https://www.cff.org/researchers/pilot-and-feasibility-awards
Path to a Cure (PTAC) Pilot and Feasibility Award
Intended to support projects that will develop and test new hypotheses and/or new methods that could eventually contribute to
the development of a cure for Cystic Fibrosis (CF) and to support promising new investigators as they establish themselves in research areas relevant
to cystic fibrosis.
*Applicants seeking to submit proposals focused on topics such as mucociliary clearance and airway hydration, infection and inflammation,
or non-lung manifestations of disease should apply through the Pilot and Feasibility Award mechanism.
Funding: $50 per year for up to 2 years
https://www.cff.org/researchers/path-cure-academic-programs

Investigator-Initiated Research Award:

Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care

Funding: up to $1.4M for 4 years

Ovarian Cancer Clinical Trial Academy – Early-Career Investigator Award:

Supports the addition of new early-career investigators (ECIs) to the unique, interactive virtual Clinical Trial Academy that provide intensive mentoring, national networking, collaborations and a peer group for junior faculty.

Funding: up to $1.4M for 4 years

Pilot Award:

Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.

Funding: up to $350K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663103

Breakthrough Award Level 1 and 2 (LOI):

Supports promising research with high potential to lead to or make breakthroughs in breast cancer.

Funding: up to $2.4M for 4 years

Breakthrough Award Level 3 (Pre-proposal):

Supports promising research with high potential to lead to or make breakthroughs in breast cancer.

Funding: up to $5M for 4 years

Clinical Research Extension Award (LOI):

Supports the extension or expansion of data collection, followup, and analysis of breast cancer clinical studies.

Funding: up to $5M for 4 years

Era of Hope Scholar Award (LOI):

Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.

Funding: to $3.5M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101

Seeking innovative approaches to address the critical questions that could present a paradigm shift for brain tumour research or use unexplored paths to allow for new discoveries to be made. Funding for collaborative discovery teams with transformational research ideas.
The award is open to international researchers but applications including a UK collaborator will be looked on favourably. Teams should be formed of researchers across
at least two/three institutions from multidisciplinary backgrounds.
Funding: up to £1.5M per program over five years.
https://www.thebraintumourcharity.org/funding-for-brain-tumour-researchers/research-grants/quest-for-cures-collaborative-discovery-teams/

To fund projects that will bridge the gap between the research happening in the lab and getting new treatments to clinic.
This funding is intended to cover key ex vivo/in vivo proof of concept studies with the aim of delivering focused research. Projects should have a
clear pathway to patient benefit and can cover any modality for any primary brain tumour.
Funding: £300K – £400K per project over 12 – 18 months.
https://www.thebraintumourcharity.org/funding-for-brain-tumour-researchers/research-grants/translational-award/

To support any innovative research (basic or translational) aimed at the development of therapeutic strategies. All biomedical disciplines are eligible.
Funding: €25K for 24 months
https://www.inshs.cnrs.fr/en/node/7274

Supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS).
FPWR accepts applications in all areas of research relevant to PWS, but we are particularly interested in supporting projects
that will lead to new interventions to alleviate the symptoms associated with PWS.
Funding priority areas include:
– Genotype to phenotype: understanding PWS genetics / how loss of PWS-critical region genes leads to the phenotype
– Neurobiology of hunger / feeding behavior and metabolism in PWS.
– Neurobiology of cognition, maladaptive behavior, and mental health in PWS.
– Clinical care research: evaluation of existing drugs and interventions to improve the significant clinical concerns in PWS.
– Therapeutics development for PWS- Genetic therapies; novel or repurposed pharmaceuticals; and devices.
Funding: Up to $150K for 18 months (with the possibility of a second grant period of 18 months of funding upon competitive renewal, 8% Overhead).
https://www.fpwr.org/request-for-applications

Discovery Award:

Supports innovative, untested, groundbreaking research that provides new insights and explores early concepts in battlefield burn care that provides the foundation for future translational and/or clinical research

Funding: up to $200K for 2 years

Patient-Centered Research Award:

Bridges the gap between research, practice, and policy by building a knowledge base that provides clinically useful findings about how interventions, clinical practices/guidelines, tools, and policies can be deployed to burn patients in an austere, resource-limited, battlefield environment at the point of need.

Funding: to $1.7M for 4 years

Technology/Therapeutic Development Award:

Supports the translation of promising preclinical findings into burn products for clinical application in an austere, resource-limited, battlefield environment.

Funding: to $1.7M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=665101

Idea Development Award:

Promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation in the rare cancers field.

Funding: to $490K for 3 years

Resource and Community Development Award:

Supports the development of research resources and clinical or preclinical data sets that advance the field of rare cancers research and ultimately improve outcomes of individuals with rare cancers.

Funding: to $1.12M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=665103

Concept Award:

Supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Proof-of-concept is the anticipated outcome

Funding: up to $140K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=665103

Clinical/Translational Research Award:

Supports translational studies that have moved beyond the realm of basic research and have the potential to result in a near-term impact in clinical research or the clinic.

Funding: up to $1.35M for 4 years

Idea Development Award: Supports the development of innovative, high-impact ideas that advance the understanding of DMD and ultimately lead to improved outcomes.

Funding: to $350K for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=667101

The Frick Foundation is looking for talented early-career scientists who have already produced excellent supervised work, ready to work independently and shows potential to be a research leader. Post-doctoral fellows are not eligible. Two researchers will receive 100,000 Swiss francs each that can be used over 2 years.
Researchers of any nationality with 5 years of experience since completion of their PhD, a scientific track record showing great promise and an excellent research proposal.
https://frick-fondation.ch/

Supports research on metastatic invasive lobular carcinoma (mILC) that will unlock new knowledge about lobular breast cancer, advance patient care and/or improve patient outcomes of those impacted by mILC. Research to identify better methods of detection, specific treatments and to eradicate lobular breast disease.
Funding: up to $200,000 per year (combined direct and indirect costs) for up to two years.
https://www.komen.org/breast-cancer-research/grants/opportunities/
www.komen.org/wp-content/uploads/2025-Komen-LBCA-LOI-Announcement-and-Instructions.pdf

Aims to de-risk early projects to facilitate further drug discovery research, funding, or partnering, for projects with strong therapeutic potential to deliver patient benefit. Applications for early drug discovery proposals from across all cancer indications and modalities. Some examples of projects we might fund include the following areas:
– deconvolution and validation of novel targets and pathways
– novel therapeutic approaches to validated targets
– development of platforms, assays and screens to identify novel cancer therapeutics or targets
– drug discovery feasibility and progressing more advanced assets
Funding: up to £250K for up to 18 months
https://www.cancerresearchuk.org/funding-for-researchers/our-funding-schemes/therapeutic-catalyst

This opportunity supports early-career researchers with a research track record of proven excellence in the molecular life sciences.
Funding: €100K for research equipment and consumables over a 3-year period.
https://www.febs.org/funding/excellence-awards/

To encourage and support early-career investigators to conduct lung cancer research and establish successful careers in this field. The proposed project may be basic, translational, clinical, or population-based research in nature and must have direct applicability and relevance to lung cancer.
* For PI who received first faculty position within the past 6 years before September 1, 2025.
Funding: $250K for 2 years (No overhead)
https://www.aacr.org/grants/aacr-career-development-awards-lung-cancer-research/

To encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.
* For PI’s that started their first independent faculty position with the title of assistant professor within the past 6 years from the grant start date (i.e., cannot have held an independent faculty position before November 1, 2019).
Funding: $225 for 1 year
https://www.aacr.org/grants/aacr-gertrude-b-elion-cancer-research-award-2/

Early-Stage Investigators
For Early-Stage Investigators aim to empower and support cancer researchers, help launch their careers, and enable them to become thought leaders in the field.
These grants are intended to provide talented investigators with the resources and dedicated time to establish innovative, emerging research projects. Projects may be exploratory, developmental, or proof of concept.
* For PI’s that started their first independent faculty position with the title of assistant professor within the past 6 years from the grant start date (i.e. cannot have held an independent faculty position before December 1, 2019).
Funding: $1M for 3 years (No overhead)
https://www.aacr.org/grants/aacr-trailblazer-research-grant-early-stage-investigator/
Mid-Career Investigators
support cancer researchers at this critical juncture in their careers and enable them to make impactful advances against cancer. Projects may be exploratory, developmental, or proof of concept. By funding innovative and paradigm-shifting research, these grants aim to advance the understanding of cancer biology, drive groundbreaking translational discoveries, and/or improve patient outcomes.
* For PI’s that received their first NIH R01 (or equivalent) award within the past 10 years from the grant start date.
(i.e., grant cannot have been awarded before December 1, 2015).
Funding: $1M for 3 years (No overhead)
https://www.aacr.org/grants/aacr-trailblazer-cancer-research-grant-mid-career-investigator/

(another deadline on 3.11)
Funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s (not for research which is directed at symptomatic relief).
Funding: £250K for 5 years
https://cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant/

Funds preclinical and clinical research focused on slowing, stopping, or reversing Parkinson’s (not for research which is directed at symptomatic relief).
Funding: £250K for 5 years
https://cureparkinsons.org.uk/research/for-researchers/apply-for-funding/quarterly-research-grant/

Recognize outstanding young researchers and scientists from around the world whose work represents an extraordinary contribution to skin research and has the potential to pave the way for new and improved treatments for skin diseases.
Funding: $100K
https://leo-foundation.org/en/grants-and-awards/leo-foundation-awards/

Annual European and Middle East award to encourage clinicians and researchers to increase insight into immune thrombocytopenia (ITP) or to improve knowledge of the Spleen Tyrosine Kinase (SYK) inhibition as mechanism of action.
Funding: €50K per 18 months
https://www.grait-awards.com/en/home

Focused on innovative ideas related to albumin and its role as a therapeutic product. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life and Pharmacoeconomics.
Funding: €50K per 12 months
https://www.albus-awards.com/en/the-award

To foster a scientific network and also the knowledge in the use of Antithrombin as a therapeutic product. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life and Pharmacoeconomics.
Funding: €50K per 12 months
https://www.gatra-awards.com/en/the-award

Support interdisciplinary research teams to rethink established paradigms and explore new paths in dementia-causing neurodegeneration.
Looking for high-risk, exploratory basic research that goes beyond conventional approaches to uncover fundamental disease mechanisms.
The aim is to drive transformative progress and lay the basis for future preventive and therapeutic breakthroughs.
* For Interdisciplinary research teams consisting of 2-5. Majority of PI’s must be at a German institution, Co-PIs can be from international institutions.
Teams that ideally comprise a balanced mix of early-career and senior researchers.
Funding: 2M EUR for 5 years
https://www.volkswagenstiftung.de/en/funding/funding-offer/next-rethink-neurodegeneration

Provide more experienced researchers with seed funding to enable them to collect the preliminary data needed to obtain major,
long-term funding from other organizations.
Funding: $100K for 1 year (No overhead, with possible 1 more year renewal)
https://hdfoundation.org/apply/

Awarded to seasoned researchers seeking to make consequential translational discoveries that will drastically alter clinical care for pregnant people and babies, whether through evidence-based prevention, diagnosis, or intervention.
Areas of research:
– Spontaneous preterm birth.
– Decreasing Maternal and Infant Morbidity and Mortality by Improving Access to High Quality Health Care.
– Cardiovascular health conditions developed during pregnancy or exacerbated during pregnancy.
Funding: $200K for 2 years
https://www.marchofdimes.org/our-work/research/grants-awards/discovery-research-grants

Nominees are scientific leaders who have pioneered research to advance our understanding of prenatal development and pregnancy and parturition. March of Dimes looks for candidates whose work involves translational and impactful scientific discoveries that may lead to interventions or preventions that improve the health of moms and babies.
Funding: Cash prize, commemorative award, and a President’s Talk at the Society for Reproductive Investigation Annual Meeting
https://www.marchofdimes.org/our-work/research/grants-awards/march-of-dimes-richard-b-johnston-jr-md-prize

Candidates must have been widely involved in maternal-fetal nutrition through teaching, research, and/or clinical practice for at least five years; shown a demonstrable effect in raising the quality of maternal-fetal nutritional care through scholarly pursuits, research, education, and/or practice; and demonstrated an ability to apply maternal-fetal nutritional standards of practice and/or facilitate their implementation by others.
Funding: A cash prize, a commemorative award reflecting the honor, and a presentation at the Pediatric Academic Society annual meeting
https://www.marchofdimes.org/our-work/research/grants-awards/agnes-higgins-award-maternal-fetal-nutrition

Melanoma Academy Leadership Award:

Supports visionary individuals who are established melanoma investigators with a strong record of mentoring and a commitment to leadership.

Funding: up to $1.3M for 4 years

Melanoma Academy Scholar Award:

supports the addition of new Scholars to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations and a peer group for early-career melanoma investigators/faculty. • Requires a Career Guide who is an experienced melanoma researcher with melanoma funding.

Funding: up to $550K for 3 year

Survivorship Research Award

Supports a broad range of innovative and impactful survivorship research that has the intended outcome of improving the health and well-being of melanoma survivors (active- or post-treatment), their families and/or their caregivers.

Funding: to $725K for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103

Topic Areas

AUTOIMMUNE DISORDERS AND IMMUNOLOGY

• Celiac Disease • Eczema • Food Allergies • Guillain-Barré Syndrome • Inflammatory Bowel Disease • Multiple Sclerosis • Proteomics • Scleroderma

CARDIOVASCULAR HEALTH

Cardiac Health • Congenital Heart Disease • Proteomics

INFECTIOUS DISEASES

• Congenital Cytomegalovirus • Far-UVC Germicidal Light • Hepatitis B • Malaria • Post-Acute Sequelae of SARS CoV-2 Infection • Proteomics • Tick-Borne Dis

INTERNAL MEDICINE

• Endometriosis • Focal Segmental Glomerulosclerosis • Interstitial Cystitis • Menopause • Nephrotic Syndrome • Pancreatitis • Polycystic Kidney Disease • Proteomics • Reconstructive Transplantation • Vision

NEUROSCIENCE AND BEHAVIORAL HEALTH

• Autism • Dystonia • Eating Disorders • Hydrocephalus • Maternal Mental Health • Myalgic Encephalomyelitis/Chronic Fatigue Syndrome • Parkinson’s • Peripheral Neuropathy • Proteomics • Sleep Disorders and Restrictions • Suicide Prevention • Traumatic Brain Injury

ORTHOPAEDIC MEDICINE

• Orthotics and Prosthetics Outcomes • Proteomics

RARE DISEASES AND CONDITIONS

• Angelman Syndrome • Ehlers-Danlos Syndrome • Epidermolysis Bullosa • Fibrous Dysplasia/McCune-Albright Syndrome • Fragile X • Frontotemporal Degeneration • Hereditary and Acquired Ataxia • Hermansky-Pudlak Syndrome • Mitochondrial Disease • Myotonic Dystrophy • Neurofibromatosis • Proteomics • Rett Syndrome • Sickle-Cell Disease • Tuberous Sclerosis Complex • Von Hippel-Lindau Disease

RESPIRATORY HEALTH

• Burn Pit Exposure • Proteomics • Pulmonary Fibrosis • Respiratory Health

Clinical Trial Award:

Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY25 PRMRP topic areas and FY25 PRMRP strategic goals.

Funding: up to $8M for 4 years

Technology/Therapeutic Development Award:

Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals.

Funding: up to $2.5M for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671101

Focused Program Award – Rare Melanomas:

Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects. The completion of one project should not be dependent on the completion of another project.

Funding: up to $2M for 4 years

Idea Award:

Supports new ideas that represent highrisk/high-gain approaches to melanoma research that are beyond an incremental advancement.

Funding: up to $400K for 2 years

Team Science Award:

Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts.

Funding: up to $1.3M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103

Clinical Consortium Award:

Supports a consortium that will facilitate the rapid execution of collaborative phase 2 or phase 2-linked phase 1 (phase 1/2) clinical trials that will bring to market high-impact, novel therapeutic interventions, which will significantly decrease the impact of prostate cancer

Funding: up to $7.6M for 4 years

Idea Development Award:

Supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY25 PCRP Overarching Challenges.

Funding: up to $1.5M for 2 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671101

seeking collaborative, multisite clinical repurposing trials to address Meniere’s disease, as well as other related vertigo and hearing loss-related diagnoses, such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis, to improve patient outcomes and quality of life. CWR may also accept translational preclinical repurposing studies that are designed to advance repurposed therapies to clinical trials or combination preclinical/clinical studies that together produce robust data for publications, presentations, follow on funding and potential off label use of repurposed therapies.

Funding: up to $350,000 for collaborative, multisite clinical trials. CWR may also accept

budgets up to $100,000 for translational preclinical studies for this RFP. Submitted budgets must include the required institutional match.

www.cureswithinreach.org/programs/funding-opportunities-rfps

www.cureswithinreach.org/wp-content/uploads/2025/03/CWR-Menieres-Disease-RFP-2025.pdf

The FNIH will continue a long tradition of highlighting outstanding researchers with the launch of the Montrone-Seigel Prize in Biomedical Sciences. This award recognizes breakthroughs in basic, clinical, or translational research led by promising scientists aged 52 or younger.

The prize comes with a $100,000 honorarium.

https://montroneseigelprize.evalato.com/

The Prize of 500,000 Swiss francs recognizes researchers worldwide for outstanding achievements in medicine, chemistry and physics.

This year, the Gretener-Thürlemann Prize will be awarded to outstanding researchers in the field of translational/clinical medicine. Scientists can apply to the management of their institution, which will then submit their nomination.

https://www.news.uzh.ch/en/articles/news/2025/gretener-thuerlemann-prize.html

This program seeks to advance the development of innovative molecular MRI (mMRI) techniques that directly quantify molecular and cellular events in Parkinson’s disease (PD).

Funding: Up to $400,000 for up to 2 years

https://www.michaeljfox.org/grant/molecular-mri-biomarker-program

to support the generation of preliminary data, perform secondary analysis of existing data, initiate feasibility studies, develop research methodology, or create tools to position the recipient to successfully apply for future longer-term funding of novel and impactful research that addresses significant knowledge gaps in women’s health issues for people with MS. This will be accomplished through a two-year research grant style mechanism, with a $200,000 maximum direct costs budget

https://www.nationalmssociety.org/for-professionals/for-researchers/research-funding-opportunities/request-for-applications

Aim: to address the health needs of cats throughout their entire lifetime by focusing on all aspects of physical, mental, and social well-being. We embrace the One Health model as a critical tool in achieving our vision. EveryCat awards grants to scientists and professionals in research which concerns the origins of feline illness, diagnosis of feline diseases, development of effective treatments, and the identification of disease prevention strategies.

Funding: up to $50,000

https://everycat.org/the-latest/grants/open-grant-rfps/

Recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality.

Funding: $125 to be used at the discretion of the recipient, also includes a $200,000 fellowship award at the recipient’s institution for a trainee chosen by the recipient.

https://www.nationalmssociety.org/for-professionals/for-researchers/research-funding-opportunities/awards-prizes/barancik

Focuses on the study of archaeological and related interdisciplinary data for the purposes of increasing our understanding of
human-environmental interactions over time and to ultimately contribute to mitigating contemporary environmental crises.
Seeks projects focused on the archaeology of sustainable communities and landscapes in changing climates. As sustainability is variable across different places and times, proposals should outline what the term means in the context of the project and what proxies will be used to study it.
Funding: $50K USD
https://www.nationalgeographic.org/society/grants-and-investments/rfp-enduring-impacts-archaeology-of-sustainability/

Future Earth is a global initiative focused on advancing sustainability science. Cross-Cutting Initiatives are integrative & synthesis activities that foster or require collaborations between Future Earth entities and/or facilitate research co-creation and transdisciplinary.
Funding: up to 50K EUR
https://fe.secure-platform.com/a/page/open-calls/cross-cutting-initiatives

Career Development Award – Scholar Option:

Supports the addition of a new early-career investigator (Scholars) to the unique, interactive virtual cancer center focused on fostering the next generation of cancer researchers.

Funding: up to $1.1M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671102

Clinical Trial Award:

Supports clinical trials that will progress to the next stage of study or improve the standard of care for individuals living with cancer..

Funding: to $4.2M for 4 years

Idea Award:

Supports innovative basic research that may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities.

Funding: up to $560K for 2 years

Impact Award:

Supports mature research projects that specifically focus on critical scientific or clinical cancer issues and have the potential to make a major near-term impact.

Funding: up to $1.75M for 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671102

Committed to supporting scientists from diverse backgrounds to foster creativity and innovation in addressing complex scientific challenges and strongly encourage applications from individuals who are from groups underrepresented in Alzheimer’s disease research.
* restricted to new and early investigators who have obtained their MD, PhD, or equivalent degree within the past 12 years at the time of application.
Funding: $300K for 3 years (No Overhead)
https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/alzheimers-disease-research-request-for-proposals/

New Investigator Grant Program
Intended to support investigators during their early years as an independent investigator involved in studies that have an impact on the causes and/or treatment of macular degeneration.
* restricted to new and early investigators who have received their MD, PhD or equivalent degree within the past 10 years at the time of application.
Funding: $150K per year (total value $450,000) for up to 3 years (No Overhead)
Innovative Research Grants
Intended to provide support for high-risk/high-gain age-related macular degeneration research. Applicants who are experts in another field are encouraged to apply their talents to proposing innovative research in the macular degeneration field.
Funding: max $200K per year (total value $600K) for up to 3 years (No Overhead)
https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/macular-degeneration-research-request-for-proposals/

Committed to supporting scientists from diverse backgrounds to foster creativity and innovation in addressing complex scientific challenges and strongly encourage applications from individuals who are from groups underrepresented in glaucoma research.
Funding: max $100K per year (total value $200K) for up to 2 years (No Overhead)
https://www.brightfocus.org/about/for-scientists/apply-for-a-research-grant/glaucoma-apply-for-grant/

Rewards international research proposals involving the microbiota and its implication in Women’s Health and Disease.
Funding: 200K EUR for up to 3 years
https://www.biocodexmicrobiotafoundation.com/women-health-award/microbiota-womens-health-international-call-projects

Canada Gairdner International Award
$100K awarded to outstanding biomedical scientists who have made original contributions resulting in an increased understanding of human biology and disease.
https://www.gairdner.org/award/canada-gairdner-international-award
John Dirks Canada Gairdner Global Health Award
$100K awarded for scientifically based research that has improved the health and well-being of those facing health inequities worldwide.
https://www.gairdner.org/award/john-dirks-canada-gairdner-global-health-award

Invests in collaborative research to accelerate the discovery of better treatments and cures for bone marrow failure disorders.
Accept proposals addressing these bone marrow failure disorders: Aplastic Anemia, Myelodysplastic Syndromes/Neoplasms (MDS), including MDS Transition to Acute Myeloid Leukemia (AML).
Funding: $60K over two years (Non-profit)
https://www.aamds.org/fund-your-research/grants-program

Will fund two basic research projects in the field of childhood brain tumors.
Funding: 100K EUR for 2 years
https://www.mianerifoundation.it/en/

Aimed at finding a cure for HIV, to uncover vital knowledge directly applicable to clinical or pre-clinical cure efforts. Persistent reservoirs of virus not cleared by antiretroviral therapy represent the main barrier to a cure. amfAR’s Target Grants should focus on pushing the boundaries of biomedical research to achieve sustained HIV remission or complete viral eradication. Priority will be given to clinical or pre-clinical applications studying pragmatic and scalable interventions that can be implemented globally. The research must be conducted and validated either in vivo (in PLWH, non-human primates, or humanized mice), or ex vivo (in cells isolated from PLWH or infected animals). Interventions tested exclusively in cell lines or in primary cells from HIV-negative individuals will not be considered responsive to this RFP.
At this stage, a short, pre-proposal (synopsis) is requested and selected applicants will be invited to submit a full application.
Funding: $480K over two years
www.amfar.org/research/target-grants-request-for-proposals

Clinical Trial Partnership Award: to support new or existing collaborative partnerships that will rapidly implement clinical trials with the potential to have a significant impact on the prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures.

Funding: $4.2M for up to 4 years

Investigator-Initiated Research Award: intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures.

Funding: $770K for up to 3 years

Translational Research Partnership Award: to support new or existing collaborative partnerships to pursue translational research that will accelerate the movement of promising ideas in military related toxic exposure research into clinical applications, including health care products, interventions, technologies, and/or clinical practice guidelines.

Funding: $2.24M for up to 3 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=677101

Aims to promote increased European diabetes research and to raise public awareness and political understanding of the magnitude and burden of the disease.
Funding: up to 100K EUR for 1 year or longer (In exceptional cases, applications for funding in an amount larger than Euro 100,000 and up to Euro 250,000 may be considered for funding).
https://www.europeandiabetesfoundation.org/workshops/78-efsd-and-lilly-european-diabetes-research-programme.html

Actively fund and advocate for research of non-hormonal, reversible male contraception, to make innovative methods of male birth control a reality.
Funding: up to $400K for a 2-year project.
https://www.malecontraceptive.org/funding-opportunities.html

Funds grants that support basic, translational or clinical research, which may lead towards cures and better treatments for
childhood cancers.
Funding: $75K/yr for 2 years
https://www.bepositive.org/research

Supports innovative, investigator-led research focused on the human gut microbiota. Jointly supported by Yakult and Nature Portfolio, the program aims to advance scientific understanding of the critical role the gut microbiome plays in human health.
Funding: up to $100K for up to 12 months
https://www.nature.com/immersive/gutgrants/index.html

Honors groundbreaking research by early-career scientists in Gastrointestinal and Inflammatory Diseases, Neuroscience and Oncology.
Funding: Each category winner will receive an unrestricted prize of $75K, one category winner will then be selected as grand prize winner and receive an additional unrestricted prize of $175K. Shortlisted applicants and winners also receive a 12-month Nature Masterclasses Career Development Program.
https://www.nature.com/immersive/innovatorsinscience/index.html

Team Science Award on Advancing Therapies Toward CURING EGFR Mutated Lung Cancers
The overarching theme of the proposals should be centered around understanding and overcoming mechanisms of resistance to treatment for EGFRmut+ lung cancer.
Funding: max of $1.5M for 3 years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-RFP-EGFR.pdf

Boehringer Ingelheim Early Investigator Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer
Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. Encourage applications on a wide variety of topics related to HER2-mutant lung cancer.
Funding: max of $250K over two years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-LCRF-BI-HER2-early-career-RFP.pdf

Boehringer Ingelheim Team Science Award on Innovative Therapeutic Strategies to Understand and Treat Lung Cancers Harboring HER2 Mutations
Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. The proposal must include studies in patients with lung cancer harboring HER2 mutations.
Funding: max of $1.5M for 3 years (Non Profit)
https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-LCRF-BI-HER2-Team-Science-RFP.pdf

https://www.lungcancerresearchfoundation.org/research/funding-opportunities-late-2025/

Designed to support the future of basic and translational lab-based research in hematology for talented junior researchers.
EHA Junior Research Grant
Received a PhD less than four years before the closing date.
Funding: €50K per year for 3 years

EHA Junior Research Grant

EHA Advanced Research Grant
Received a PhD four to eight years before the closing date.
Funding::€80K per year for 3 years
https://ehaweb.org/research-innovation/grants/eha-advanced-research-grant
* If your research focuses on hemoglobinopathies or precision hematology, you can apply for a version of the EHA Research Grant known as a Topic-In-Focus Research Grant.
https://ehaweb.org/research-innovation/grants/about-our-eha-research-grants

Bilateral Collaborative Grant
Designed to support the future of basic and translational lab-based research in hematology. For collaboration between two independent research groups with complementarity of expertise, showing a mutual need to answer a specific research question.
Funding: €160K per year for 2 years
https://ehaweb.org/research-innovation/grants/eha-bilateral-collaborative-grant
Kick-Off Grants
Support new research questions that lack solid preliminary data. They ‘kick-off’ novel concepts and ideas and support high-risk but potentially high-impact research ideas that don’t yet have proof of principle data. For early-career researchers.
Funding: total award of up to €50K for 1 year
https://ehaweb.org/research-innovation/grants/eha-kick-off-grant

A groundbreaking research initiative focused on better understanding neuroinflammation’s role in brain disease that promises to transform the future of brain health. For translational research with a focus on clinical impact, carried out through two types of grants:
Breakthrough Grants
Designed to support interdisciplinary teams investigating novel neuroinflammation mechanisms and the potential development of new biomarkers, therapeutic targets, or technologies.
Funding: two Breakthrough Grants of up to $2M each for 2 years
Catalyst Grants
Intended to help researchers overcome critical research hurdles and offer flexibility to explore bold ideas that have the potential to lead to significant advances in diagnosis, treatment, or prevention.
Funding: at least two Catalyst Grants of up to $500K each for 2 years                                                      https://www.americanbrainfoundation.org/for-researchers/#cocm

Under the canSERV Open Call researchers are welcome to apply to a portfolio of services offered by canSERV to address the research needs of the entire oncology developmental pipeline.
www.canserv.eu/calls/open-call-for-transnational-service-provision/

To accelerate research that will ultimately eliminate delivery of pre-term babies as the primary intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy by 2050.
Funding: range of $50K to $100K for a 2 year project (applications above that range will be considered with substantial justification), 5% overhead.
www.preeclampsia.org/research-funding

Invites scientists and clinicians worldwide to submit innovative studies for groundbreaking scientific research that brings us closer to effective treatments and improved care for individuals with Angelman syndrome (AS).
Funding: up to $100,000 per year for 1-2 years
https://angelman.org/call-for-proposals/

Supports research in cardiovascular and neurovascular disease. While the foundation will bear the risks inherent in innovative research, proposals should not be merely speculative, and all applicants should provide a clear hypothesis and rationale for the research plan. Networks should strive to advance knowledge which may cover a variety of interrelated topics, by capitalizing on the resources and multidisciplinary expertise available within the network. Their overarching principal aim might be, for example, to seek to understand a fundamental mechanistic question, to attempt a breakthrough on a particularly difficult research problem, or to propose a big new idea in cardiovascular or neurovascular research. Network activities should be oriented towards long term goals, not at producing pre-defined results. Leducq Foundation accepts applications in basic, translational, and clinical science, including collaborative “bench to bedside and back” programs. Applicants should aim for results that, at the conclusion of the five-year term, have the potential to advance the diagnosis, management, or prevention of human cardiovascular and neurovascular disease.
Each network is built around an international research alliance involving two network coordinators, who must be located on different continents.
Funding: up to $8,500,000 over 5 years.
www.fondationleducq.org/international-networks-of-excellence-how-to-apply/how-to-apply

MND supports biomedical research on ALS and related conditions, in all relevant disciplines, aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic.
** Applications submitted by researchers based at institutions outside of the UK and Ireland must meet the following criteria:
• the project must be unique in concept or design (ie no similar research is being performed in the UK/Ireland)
• the project must involve a significant aspect of collaboration with a UK or Irish institute
Funding: up to £315,000 over three years.
www.mndassociation.org/research/for-researchers/apply-for-funding
www.mndassociation.org/sites/default/files/2022-12/Project-Grant-Guidelines-Summary-Application-Nov-19.pdf

International programme that seeks to incentivise the use of AI-based approaches to transform therapeutic discovery for the treatment of amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND).
Funding: £100K for 9 months (20 teams)
Next stages (total 5 years for all stages):
Stage 2: Prioritize – £200K for 12 months (10 teams), Stage 3: Validate – £500K for 24 months (5 teams), Winner Award – £1M.
https://als.longitudeprize.org/

Intended for exceptional investigators who have made significant, impactful contributions to their field of research.
Pioneer Award will focus on two core strategies to address the underlying cause of cystic fibrosis: Restoring CFTR protein, Targeting the Root Cause of Disease.
* Applicants should request a funding amount necessary to complete the proposed research project, up to 3 years. It is
anticipated that the scope of work and requested funding will exceed a CFF Research Grant or a typical NIH R01 award.
https://www.cff.org/researchers/path-cure-pioneer-award
https://www.ra.trdf.co.il/files/Path to a Cure.pdf

Aim: innovative proposals that leverage a novel understanding of the enteric nervous system as well as emerging neuromodulation technologies to selectively target neurons in the small intestine and alter the body’s stress response. The CoasterChase program aims to develop a multimodal, ingestible, sensing and stimulation platform for use in monitoring and modulating biomarkers of acute stress from within the small intestine. Proposed research should investigate innovative approaches that enable revolutionary advances in enteric neuromodulation and sensing, ingestible electronics, and modulation of the stress response. Specifically excluded is research that primarily results in evolutionary improvements to the existing state of practice.

https://sam.gov/opp/82431f9c8fb14f73bfd8202a06391a03/view

Aim: to increase use of large, publicly available data resources by supporting investigators to allocate time and personnel toward working in and publishing from these previously collected data. Applications should leverage existing publicly accessible datasets to ask new questions and extract new knowledge. Priority will be given to applications that use SFARI-supported resources, although all applications will be considered as long as data are publicly accessible at the time of application. Proposed questions should be relevant to SFARI’s mission.

Informational Zoom Meeting: July 23, 2025

Funding: $300,000 for up to 2 years.

https://www.sfari.org/grant/2025-data-analysis-request-for-applications/?tab=rfa

Recognizes an individual or a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS.
Funding: $50K and travel reimbursement up to $2,500 to attend International Symposium on ALS/MND.
https://www.massgeneral.org/neurology/als/news/healey-innovation-prize-nominations

Supports interdisciplinary, collaborative, and highly synergistic projects that focus on the molecular understanding of human lupus and the heterogeneity of the disease.
Funding:
LOI- up to $10K for 3.5 months planning grant, to assemble competitive multi-institutional teams and to develop competitive proposals
Grant – up to $1M per year for up to three years
www.lupusresearch.org/for-researchers/funding-opportunities/
www.lupusresearch.org/wp-content/uploads/2025/06/2026-GTSA-RFA.pdf

Aim: innovative ideas can lead to improvements in preventing, predicting, diagnosing and treating Inflammatory Bowel Disease (IBD). This program enables researchers worldwide to test ideas, gather and share data, and collaborate to advance the understanding of IBD.

Funding: Innovator Awards support individual research projects with grants of up to $150,000 and collaborative projects involving multiple investigators with grants of up to $300,000

https://krfoundation.org/news/health/ibd-research-funding-opportunity/

https://krfoundation.org/grants/funding-opportunities/innovator-awards/

Platinum Call with UCB
Intended to fund one excellent young scientist with an already existing track record in RMD research for a project entitled: “Early predictors and drivers of PsA and axSpA disease progression”. The grant aims at supporting the initiation of an innovative independent research project. The applicant must be awarded their PhD or MD no longer than 8 years ago.
Funding: up to 100K Euro for a max period of 12 months
https://foreum.org/foreum-grants/foreum-calls-overview/foreum-platinum-call-2025-with-ucb/
Gold (plus) Call with Novartis
Intended to fund an excellent young scientist with an already existing track record in RMD research for a project entitled: “Identification of clinical/biomarker/genomic predictors in patients with Undifferentiated, or Rapidly Progressing Connective Tissue Diseases”. The applicant must be awarded their PhD or MD no longer than 8 years ago.
Funding: up to 100K Euro for a max period of 12 months
https://foreum.org/foreum-grants/foreum-calls-overview/foreum-platinum-call-2025-with-ucb-copy/
https://foreum.org/foreum-grants/foreum-calls-overview/

The Foundation is looking for talented early-career scientists who have already produced excellent supervised work, ready to work independently and shows potential to be a research leader. Two researchers will receive 100,000 Swiss francs each that can be used over 2 years. Researchers of any nationality with 5 years of experience since completion of their PhD, a scientific track record showing great promise and an excellent research proposal.
Funding: Not Specified
https://frick-fondation.ch/application

Supports the professional development of young scientists by enabling mobility and facilitating a visit to a research group in another institute. Support basic and translational early-career researchers in hematology.
Funding: up to €7,500 within Europe and €10,000 outside of Europe for a 3-month visit.
https://ehaweb.org/research-innovation/grants/eha-research-mobility-grant
www.ehaweb.org/research-innovation/grants

Supports basic and clinical research in paraplegia in Switzerland and around the world
Funding: up to 150K Swiss francs over 2 years.
www.irp.ch/en/research

Breakthrough Award Level 1 and 2 II:

Supports promising research with high potential to lead to or make breakthroughs in breast cancer. The impact may be near-term or long-term but must go beyond a minor advancement and have the potential to lead to a fundamentally new strategy or approach for preventing or ending breast cancer that is significantly more effective than current strategies or approaches. Funding: up to $3.35M for 4 years

Clinical Research Extension Award II

• Intended to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysisFunding: to $8.4M for 4 years

https://ebrap.org/eBRAP/public/Program.htm

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101

Supports the hematology-focused careers of ASH members who are trainees or early-career investigators based in countries other than the US or Canada.

* Hematology research, including basic, translational, patient-oriented, and outcomes-based research.

* Requests for training at other institutions by trainees or early-career investigators, pilot studies, collaborative projects, and other proposals for career development.

Funding: The award length may vary from 6 months to 3 years.  For projects of one year or less, applicants may request up to $100K.  For projects of more than one year, applicants may request up to $150K.

www.hematology.org/awards/career-enhancement-and-training/global-research-award

A summary is required to submit a full proposal.

Aim: to restore brain tissue, enabling individuals with brain damage to recover cognitive functions. The program seeks to develop methods to make non-specialized cells form into normal tissue. After these cells are grafted, FRONT will measure how well they integrate with the surrounding healthy neocortex tissue, proper layered structure of normal cortical tissue, and functional recovery. The goal of the program is to alleviate the personal and financial burdens of previously ‘permanent’ brain damage. The total funding or size of each award will not be disclosed. Multiple awards are anticipated, based on proposal quality and available funds.

FRONT program

https://sam.gov/workspace/contract/opp/89224bcb8aa9492ea7165891cfe9ea1f/view

Provides research funding to early-career investigators to encourage and promote quality research in global oncology and to develop the next generation of researchers to address global health needs. This is a mentored award and the research project is conducted under the guidance of a scientific mentor.
Funding: $50K for 1 year
www.asco.org/career-development/grants-awards/funding-opportunities/global-oncology-young-investigator-award

Intended to provide financial support to promising young researchers to advance the understanding of complications and therapeutic strategies in the context of hematological diseases.
Funding: €240,000 for 3 years.
https://professional.dkms.org/research-publications/research-grant

Support fundamental, translational, and clinical research projects that will strengthen the understanding, deepen the knowledge and/or will explore new therapeutic approaches for Down syndrome and other genetic diseases with intellectual disability.
The Autumn call is exclusively dedicated to Trisomy 21 research, while the Spring call is aiming at supporting fundamental, translational and clinical research programs related to research intellectual deficiencies of genetic origin solely with the exclusion of Trisomy 21.
Pilot or exploratory grants
For early-stage research projects built on preliminary data or small projects that complement larger primary projects.
Funding: €50K over 2 years
Advanced grants
For larger breakthrough projects with substantial preliminary data.
Funding: €80K over 2 years
https://www.research.fondationlejeune.org/call-for-projets/

For research proposals supporting the Polio Endgame Strategy 2022-2026. The current priority of the Polio Research Committee is to generate new data or information in the following areas:
– Vaccine schedule immunogenicity
– Surveillance
– Epidemiology/ virology
– Monitoring & Evaluation
– Basic immunology
– Containment
Funding: $50,000 – $300,000 for 12-24 months
https://polioeradication.org/what-we-do/current-research-areas/grants-and-collaborations/
https://polioeradication.org/wp-content/uploads/2016/12/PRC_ProposalGuidelines.pdf

Aim: improving outcomes for individuals with single ventricle heart disease by addressing the organ-level complications and sequelae that drive morbidity and mortality.
Priority outcomes include preventing or reversing key organ-level complications such as:

• Lymphatic dysfunction
• Liver disease
• Kidney and gut perfusion impairments
• Heart failure, valve dysfunction, and arrhythmia
• Neurodevelopmental challenges

Funding: Up to $600K over 3 years.

https://www.additionalventures.org/funding/single-ventricle-research-fund/

The Program offers up to $100K for a one-year period and are provided for established scientists pursuing particularly innovative project ideas that might provide new approaches to understanding or treating severe mental illness.  Areas of particular interest include patient populations with unique or unusual characteristics and central nervous system developments.

https://bbrfoundation.org/grants-prizes/narsad-distinguished-investigator-grants

will focus on the science behind HER2 mutations as oncogenic drivers of malignancy and/or the development of novel therapeutic approaches for patients with tumors harboring HER2 mutations.

Funding: $1,500,000 over a period of three years

website

To support high quality research on non-pharmacological treatment of symptoms experienced by patients with Parkinson’s disease and other movement disorders performed in a research center in or related to Switzerland.
The funding period is two years, with a possible extension up to a maximum of 4 years.
https://www.jggf.ch/en/neurology-research

“Outside the box” projects with the goal of bringing new light to the biology of Parkinson’s disease (PD), a new approach to PD research, or testing a truly novel therapeutic idea. Projects should be based on groundbreaking or unconventional ideas that are unlikely to be funded through more traditional funding mechanisms.
Funding: $200K for 2 years ($100K per year)
https://www.parkinson.org/advancing-research/for-researchers/awards-independent-investigators#ImpactAwards

Regular Grant Program
Supports innovative and original research into the role of diet, nutrition, body composition and physical activity in either cancer prevention or cancer survivorship.
Funding: up to £500,000 over 4 years
www.wcrf.org/research-policy/our-grant-programmes/regular-grant-programme
INSPIRE Research Challenge
Supports early career researchers (within 2–7 years full-time equivalent working in research since the award date of their PhD or equivalent higher research degree). Proposals should address modifiable factors including both lifestyle – such as diet, nutrition, physical activity – and environmental factors – such as pollution/contaminants and pathogens. Particular priority will be given to novel exposures including stress, sleep and host factors such as immune function.
Funding: up to Up to £75,000 over one year
www.wcrf.org/research-policy/our-grant-programmes/inspire-research-challenge

Aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes. We invite research groups to work with us and our partner Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants.
Funding: up to $600K.
https://www.nature.com/immersive/mdximpactgrants/index.html

Danby Research Award
The Danby Research Grant encourages research into the disease hidradenitis suppurativa (HS). The goal is the development of new clinical and translational lines of investigation in the field of HS that further patient care.
Funding: up to $30K for 1 year (No Overhead)
Translational Research Grant
The Translational Research Grants are open to applications that stimulate and support novel research ideas in the field of hidradenitis suppurativa (HS) capable of competing for long-term funding from the National Institutes of Health or other agencies in the future.
Funding: up to $100K for 1 year (No Overhead)
www.hs-foundation.org/grants-and-scholarships

NORD with Member patient organizations are accepting applications for scientific and/or clinical studies related to the following rare diseases:

* Appendix Cancer/Pseudomyxoma Peritonei (ACPMP) – two grants of up to $50K each.

* Chromosome 6, Partial Trisomy 6q – one grant of up to $30K.

* Epidermodysplasia Verruciformis (EV) – one grant of up to $25K.

* Peutz-Jeghers Syndrome (PJS) – one grant of up to $40K.

* Pseudomyxoma Peritonei (PMP) – one grant of up to $50K.

https://rarediseases.org/advancing-research/request-for-proposals

FFB supports basic, laboratory-based early translational, clinical studies, and pre-clinical research applicable to inherited retinal degenerative diseases (IRD). The goal is to find the causes, preventions, treatments, and cures for retinitis pigmentosa, macular degeneration, and the entire spectrum of retinal degenerative diseases. FFB has identified 6 Research Priority Areas: Genetic Technologies / Restorative Therapies / Novel Medical Therapies / Clinical: Structure and Function / Genetics / Cell and Molecular Mechanisms of Disease.

FFB encourages researchers from all scientific disciplines that have ideas geared toward eliminating IRDs to apply to a grant or award program. Individuals from underrepresented racial, ethnic and gender groups, as well as individuals with disabilities, are always encouraged to apply.

* Individual Investigator Research Award: designed to concentrate research in areas with the greatest potential to move toward treatments and cures for the inherited orphan retinal degenerative diseases and dry age-related macular degeneration (dAMD). Funding: up to $300K over 3 years.

* Disease Model Award: to develop, validate, or utilize non-rodent disease models (in silico, in vitro, or in vivo) for therapeutic development for IRD and dAMD. Funding: $300,000 to $1,000,000, distributed over 3 to 5 years.

* Postdoctoral Fellowship Award: supports the training of postdoctoral fellows (Ph.D. earned within the past 5 years) engaged in innovative research projects focused on IRD and dAMD. The fellowship provides financial support, allowing fellows to pursue innovative research. Working closely with mentors to foster professional growth, networking, and potential long-term collaborations. Funding: $160K over 2 years.

www.fightingblindness.org/grants-and-award-programs

Research Seed Grant: Funding is limited to $37,500 per year for two years ($75,000 total)

Young Investigator Award: Funding is limited to $50,000 per year for two years ($100,000 total)

https://pscpartners.org/research/research-grants-program/psc-partners-research-grants-application.html

Correlative Science

Seeking to generate data from clinical trials aimed at improving event free survival of recurrent and metastatic osteosarcoma patients.

Funding: $200K–$500K over two years (indirect costs not to exceed 10% of the requested project budget).

Preclinical/Translational

A translational imperative for the OSI is to cultivate and support a research agenda that will identify biological dependencies in the disease that can be targeted in patients. This research agenda will ideally include the use of novel laboratory approaches and bioinformatic tools applied to osteosarcoma cells, a diversity of in vivo models across species and human patient samples.

Funding: $500K over two years (indirect costs not to exceed 10% of the requested project budget).

High-Risk/High-Impact

The aim of this grant program is to place less emphasis on preliminary data to encourage projects exploring bold innovations that may fall within any stage of the drug development path, and that seek to deliver curative outcomes to patients with osteosarcoma.

Funding: $25K–$125K over one year (indirect costs not to exceed 10% of the requested project budget).

Clinical Trials

The primary objective of proposed Phase I/II or Phase II clinical trials in relapsed/refractory osteosarcoma should be to improve event free survival (EFS) at 4 months beyond historical rates known to be in the range of 12% for patients with unresectable disease.

Funding: Up to $80K over two to three years (indirect costs not to exceed 10% of the project budget requested).

https://osinst.org/researchers/#grants

The AABB Foundation awards grants for investigator-initiated original research in all aspects of blood banking, transfusion medicine and biotherapies.

Grant applications are evaluated on the basis of their scientific merit, relevance to and impact on transfusion medicine, focus and appropriateness to the scope of funding, and likelihood of yielding meaningful data.

Funding: up to $100K

www.aabb.org/foundation/early-career-scientific-research-grants-program

www.aabb.org/docs/default-source/default-document-library/foundation/aabb-foundation-grant-application-guide.pdf?sfvrsn=4fbed261_8

Provides seed funding for highly innovative, high-risk-high-reward research with significant potential to accelerate the mission of Breakthrough T1D. Proposals should address key outstanding questions and have the potential to lead to a challenge or a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery.

Funding: max of $200K for 1 year (includes 10% overhead)

https://www.breakthrought1d.org/explore-research/funding-opportunities/

https://www.breakthrought1d.org/wp-content/uploads/2025/09/FY26-Innovative-RFA.pdf

The MRA is pleased to offer a special opportunity to fund Pilot Awards focused on melanoma research from Israel-based researchers.

Support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

Funding: Up to $50K per year for 2 years (No Overhead)

https://www.curemelanoma.org/research/request-for-proposals/mra-grant-mechanisms

https://cdn.prod.website-files.com/65fc7713b6643108b3c7e675/689e36577224280600898147_5a1bf1eede9fd1886a08b22524d9b2ef_MRA%202025-2026%20RFP.pdf

Advancing Technologies for Spatiotemporal Omics in Live Tissue

Focused Projects: $500,000 USD total costs (inclusive of up to 15 percent indirect costs) over 24 months (maximum of $250,000 total costs per year, inclusive of up to 15% for indirect costs) for exploratory, risky technology development strategies; and

Expanded Projects: $1,000,000 USD total costs (inclusive of up to 15 percent indirect costs) over 24 months (maximum of $500,000 total costs per year, inclusive of up to 15% for indirect costs) for projects that provide end-to-end solutions for live tissue proteomics and/or metabolomics.

Implementation of Synthetic Biology Principles in Immunology

Applications can request funding of up to $600,000 USD total costs over two years (24 months), inclusive of up to 15% for indirect costs (maximum of $300,000 total costs per year, inclusive of up to 15% for indirect costs).

https://chanzuckerberg.com/science/science-funding/

Senior Research Awards
To provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources
such as the National Institutes of Health (NIH).
Funding: up to $130K per year for 1-3 years (Non-profit)
https://www.crohnscolitisfoundation.org/research/grants-fellowships/senior-research-awards
Litwin IBD Pioneers
Supports innovative clinical and translational research projects with the potential to impact the treatment of IBD patients in the near future. The program encourages novel research into the diagnosis, identification of clinically relevant subsets, treatments, and cures for inflammatory bowel diseases (IBD) and funds innovative pilot research so that scientists can test their initial ideas and generate preliminary data.
Funding: up to $130K per year for up to 2 years (Non-profit)
https://www.crohnscolitisfoundation.org/research/grants-fellowships/litwin-ibd-pioneers

PACE, a collaboration between 3 leaders in the UK’s health innovation & research community, supports high value, high risk, early phase drug discovery and diagnostic projects for antibacterial therapeutics.
PACE seeks projects in Hit-to-Lead or Lead Optimisation phases, seeking to treat Gram-negative bacterial infections associated with the highest burden of AMR, as highlighted by the Lancet studies[1]. Indications in scope are: lower respiratory tract infections (LRTI), blood stream infections (BSI) and complicated urinary tract infections (cUTI). Therapeutics must target one or more drug-resistant priority Gram-negative pathogens: Enterobacteriaceae (prioritising E. coli and K. pneumoniae), A. baumannii and/ or P. aeruginosa[2].
PACE seeks for innovative and differentiated projects with the potential to address drug-resistant infections where treatment options are limited. Funded projects will be expected to demonstrate strong potential to meet the WHO innovation criteria[3] (a new chemical class; a new target; a new mechanism of action; the absence of cross resistance), focusing on candidates with the greatest likelihood of delivering meaningful clinical benefit.
Funding: Up to £6 million is available to support up to 8 projects, with a maximum of £1 million available per project.
[1] www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01867-1/fulltext
[2] www.who.int/publications/i/item/9789240093461
[3] https://iris.who.int/bitstream/handle/10665/376944/9789240094000-eng.pdf

Resilience of the gut microbiome following perturbations and their implications to human health and disease.
Perturbations (of the gut microbiome) may involve, but not exclusively, drugs, life styles factors, smoking…
The project should address mechanisms. Funding should not be used for a randomized controlled trial but can include
the use/ analysis of samples collected from clinical trials.
Funding: up to €200K per year for up to 3 years.
https://www.biocodexmicrobiotafoundation.com/international-research-grant/international-call-projects

Funds data/AI-driven approaches that answer cancer research questions addressing cancers in children and young people and aligns with our research data strategy. The goal of the award is to generate novel insights about children’s and young people’s cancers, and in doing so, create or improve data and/or data resources for the wider research community. We particularly welcome proposals in target identification or AI implementation.
*Include at least one lead or joint lead applicant with an evidenced track record of expertise in data science or AI.
*Include at least one lead or joint lead applicant working in children’s and young people’s cancers.
*Include at least one UK-based co-investigator.
Funding: up to £2.5M for 5 years (No Overhead)
https://www.cancerresearchuk.org/for-researchers/apply-for-and-manage-your-funding/our-funding-schemes/data-for-children-young-people-cancer-award#overview

Supports an innovative and collaborative group of researchers working together to improve our understanding of the biological mechanisms that underlie bipolar disorder. Especially encourage applications that address the cellular and molecular mechanisms of mood-state switching; biological mechanisms by which manic or depressive episodes are induced by external risk factors; or using experimental pharmacology to test causality of a molecular or circuit-level mechanism underlying mood-state switching.
Funding: op to $4.5M over 3 years
https://www.bipolardiscoveries.org/funding/rfa-opportunities/

The Accelerator will identify human health research with the potential to transform the human healthspan. Designed to maintain scientific rigour and integrity throughout the translation process the program provides you with the tools and connections to translate your groundbreaking research for maximum impact.
Funding: an unrestricted cash award of $10,000
www.nature.com/immersive/healthspanaccelerator

This ARIA Program seeks to unlock the capability of dramatically accelerating the adaptation of no domesticated species to new environmental conditions. The resulting transformative paradigm for conservation and ecological engineering will complement traditional environmental protection and stewardship strategies. By accelerating adaptation of key ecosystem members or functions, we aim to help preserve ecological interactions and maintain or recover important functions and services despite environmental changes.
Funding: up to £500K
*Outside of programs, we award seed funding to individuals or teams pursuing research aligned with our opportunity spaces. With smaller budgets and less structure than programs, seeds support researchers to uncover new pathways that might otherwise fall through the cracks.
https://www.aria.org.uk/opportunity-spaces/engineering-ecosystem-resilience

Focused on understanding the fundamental biology of genetic and sporadic forms of ALS to help uncover the next wave of therapeutic targets.
Seeking applications from multidisciplinary groups with novel and innovative methods in convergent and complimentary multi-omic approaches, and applications of artificial intelligence and machine learning.
Collaborative projects for this call comprise groups of 3-5 laboratories working around a common theme or target.
Funding: up to $500 per year for 2 years ($130K per lab, per year max).
https://www.targetals.org/basic-biology-consortia/